<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Non-falciparum malaria: P. vivax, P. ovale, and P. malariae</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Non-falciparum malaria: P. vivax, P. ovale, and P. malariae</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Non-falciparum malaria: P. vivax, P. ovale, and P. malariae</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ric N Price, MD, FRCP, FRACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert J Commons, MBBS, FRACP, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Johanna Daily, MD, MSc</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 26, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Non-falciparum malaria refers to malaria infection due to <em>Plasmodium</em> species other than <em>P. falciparum</em>; these include <em>P. vivax</em>, <em>P. ovale</em>, <em>P. malariae</em>, and <em>P. knowlesi</em>  (<a class="graphic graphic_table graphicRef53291" href="/z/d/graphic/53291.html" rel="external">table 1</a>). </p><p>Worldwide, the greatest mortality due to malaria is associated with <em>P. falciparum</em> infection. However, the non-falciparum malarias<em> </em>can also cause significant morbidity and mortality, including clinical deterioration after initiation of treatment [<a href="#rid1">1,2</a>]. <em>P. vivax</em> malaria is a relapsing illness with recurrent episodes of malaria leading to a cumulative risk of severe anemia and associated comorbidities [<a href="#rid3">3,4</a>]. Infection with <em>P. ovale</em> also causes a relapsing illness but infrequently causes severe illness, whereas <em>P. malariae</em> results in chronic low level parasitemia and associated anemia which can be severe<em> </em>[<a href="#rid5">5-8</a>].</p><p>The epidemiology, clinical manifestations, diagnosis, and treatment of non-falciparum malaria due to <em>P. vivax, P. ovale,</em> and <em>P. malariae</em> in nonpregnant adults and children will be reviewed here. Issues related to non-falciparum malaria in pregnant women are discussed separately, as are issues related to malaria caused by <em>P. falciparum</em> and <em>P. knowlesi</em>. (See  <a class="medical medical_review" href="/z/d/html/5704.html" rel="external">"Treatment of uncomplicated falciparum malaria in nonpregnant adults and children"</a> and  <a class="medical medical_review" href="/z/d/html/5667.html" rel="external">"Treatment of severe malaria"</a> and  <a class="medical medical_review" href="/z/d/html/4812.html" rel="external">"Malaria in pregnancy: Prevention and treatment", section on 'Non-falciparum malaria'</a> and  <a class="medical medical_review" href="/z/d/html/112633.html" rel="external">"Non-falciparum malaria: Plasmodium knowlesi"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The epidemiology of non-falciparum malaria varies depending on the species, as described in the following sections. Issues related to <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> susceptibility are most significant in the setting of <em>P. vivax</em> infection, as discussed below.</p><p class="headingAnchor" id="H2639591244"><span class="h2">Non-falciparum malaria species</span></p><p class="headingAnchor" id="H1692802959"><span class="h3">Plasmodium vivax</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Global distribution</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Worldwide</strong> – <em>P. vivax</em> is the second most common cause of human malaria after <em>P. falciparum</em>; in 2021 there were an estimated 4.9 million cases [<a href="#rid9">9</a>]. There is endemic transmission throughout most of the tropics including Africa, Asia, the South Pacific, and Central and South America; approximately one-third of the world population is at risk of infection [<a href="#rid9">9,10</a>]. An estimated 82 percent of the global vivax burden arises from four high-burden countries: India, Pakistan, Ethiopia, and Sudan [<a href="#rid10">10</a>]. </p><p></p><p class="bulletIndent2"><em>P. vivax</em> causes only 2 percent of malaria attacks worldwide; this relatively small proportion may be attributed to the huge burden of <em>P. falciparum</em> in sub-Saharan Africa, where the prevalence of <em>P. vivax</em> is low [<a href="#rid11">11,12</a>]. Outside of sub-Saharan Africa, intense malaria control activities in countries where both <em>P. falciparum</em> and <em>P. vivax</em> are endemic have led to a declining burden of <em>P. falciparum</em> but a concomitant rise in the proportion of malaria due to <em>P. vivax, </em>which is now the predominant cause of malaria<em> </em>in 31 of 49 countries where<em> P. vivax </em>is endemic [<a href="#rid13">13</a>]<em>.</em></p><p></p><p class="bulletIndent2">In most areas where <em>P. vivax</em> is prevalent, malaria transmission rates are low (the island of New Guinea is an exception). Many individuals achieve a level of immunity that permits asymptomatic submicroscopic infections; however, people of all ages are at risk of symptomatic infection. Among travelers diagnosed with <em>P. vivax</em> in North American or European clinics, those visiting friends and relatives in India and Pakistan are at greatest risk [<a href="#rid14">14</a>]. Local outbreaks of <em>P. vivax</em> infection have occurred as a result of transmission of infection from migrant workers to local Anopheline mosquitoes in Greece and the United States [<a href="#rid15">15,16</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>United States</strong> – Locally acquired mosquito-transmitted (autochthonous) cases of <em>P. vivax</em> were reported in the United States (Florida and Texas) in 2023 [<a href="#rid17">17</a>]. The occurrence of these cases underscores the potential for imported malaria cases in regions with competent vectors to produce local mosquito transmission of malaria parasites.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relapse</strong> – Both <em>P. vivax</em> and<em> P. ovale</em> form dormant liver stages (hypnozoites) that can activate weeks, months, or years after the initial infection, causing relapse [<a href="#rid18">18</a>]. The frequency and timing of these relapses varies considerably with the geographic region and the sporozoite inoculum [<a href="#rid19">19</a>]. Relapses are an important source of ongoing transmission, undermining control and elimination efforts [<a href="#rid13">13,20</a>]. They account for 66 to 95 percent of all recurrent vivax malaria episodes [<a href="#rid21">21</a>]. (See <a class="local">'Relapse'</a> below and <a class="local">'Preventing relapse'</a> below and <a class="local">'Recurrent infection'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of Duffy factor</strong> – The absence of Duffy factor on the surface of red blood cells among most Africans was previously believed to protect most West and Central African populations from malaria due to <em>P. vivax</em>. However, additional evidence suggests that <em>P. vivax</em> transmission is possible even among Duffy antigen-negative populations in East and West Africa, the Amazon River basin, and Madagascar [<a href="#rid12">12,22-26</a>]. The true prevalence of <em>P. vivax</em> infection and the frequency and character of associated morbidity among Duffy-negative individuals in Africa remain largely unexplored. (See  <a class="medical medical_review" href="/z/d/html/7099.html" rel="external">"Protection against malaria by variants in red blood cell (RBC) genes", section on 'Duffy blood group system'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mortality</strong> – The reported risk of mortality associated with <em>P. vivax</em> infection varies considerably [<a href="#rid2">2</a>]. The greatest risk occurs in vulnerable populations in endemic settings with recurrent episodes of malaria, resulting in a cumulative risk of severe anemia and associated comorbidities [<a href="#rid27">27</a>]. Among patients presenting with severe disease, mortality ranges from 5 to 25 percent, confounded by bacterial coinfection in the context of severe anaemia [<a href="#rid4">4,28-33</a>]. Young infants and pregnant women are at particular risk [<a href="#rid34">34,35</a>]. Nonimmune travelers are also at risk for life-threatening illness [<a href="#rid36">36,37</a>], although mortality in nonendemic resource-rich settings is generally lower compared with endemic settings [<a href="#rid6">6</a>].</p><p></p><p class="headingAnchor" id="H2392538086"><span class="h3">Plasmodium ovale</span><span class="headingEndMark"> — </span><em>P. ovale</em> malaria is endemic to tropical western Africa. It is also endemic in Southeast Asia and Oceania, but is rarely seen in conventional prevalence surveys in these areas [<a href="#rid38">38</a>]. Sensitive molecular diagnostic methods applied in the Asia-Pacific typically demonstrate <em>P. ovale</em> prevalence of about 0.2 percent in most endemic areas. In one survey in Indonesia including more than 15,000 blood smears, 34 individuals with <em>P. ovale </em>infection were identified; the frequency of <em>P. ovale</em> relative to <em>P. falciparum</em> and <em>P. vivax</em> was &lt;1:1000 [<a href="#rid39">39</a>]. </p><p>There are two distinct subspecies of<em> P. ovale</em>: <em>P. ovale curtisi</em> and <em>P. ovale wallikeri</em> [<a href="#rid40">40</a>].</p><p>Similar to <em>P. vivax</em>, <em>P. ovale</em> forms dormant liver stages (hypnozoites) that can activate weeks, months, or years after the initial infection, leading to relapses [<a href="#rid18">18</a>]. (See <a class="local">'Relapse'</a> below and <a class="local">'Preventing relapse'</a> below.)</p><p>Severe complications may arise with <em>P. ovale</em> infection, including jaundice, anemia, and respiratory syndromes; however, these are infrequent compared with severe <em>P. falciparum </em>malaria. Mortality associated with <em>P. ovale</em> infection is estimated to be 0.15 percent [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H938178689"><span class="h3">Plasmodium malariae</span><span class="headingEndMark"> — </span><em>P. malariae</em> infection occurs throughout Africa, Asia, Oceania, and the Americas [<a href="#rid41">41</a>]. In general, <em>P. malariae</em> occurs sporadically in areas of stable malaria transmission, although at a relatively low prevalence [<a href="#rid42">42,43</a>]. <em>P. malariae</em> is unique in its ability to cause attacks even decades after exposure; the mechanism of persistence is unknown [<a href="#rid44">44</a>].<em> P. knowlesi</em> may be misdiagnosed as <em>P. malariae</em> microscopically. (See  <a class="medical medical_review" href="/z/d/html/112633.html" rel="external">"Non-falciparum malaria: Plasmodium knowlesi", section on 'Diagnosis'</a>.)</p><p>Severe complications may arise with <em>P. malariae</em> infection, including jaundice, anemia, and respiratory syndromes; however, these are infrequent compared with severe <em>P. falciparum </em>malaria. Mortality associated with <em>P. malariae</em> infection is estimated to be 0.2 to 2.4 percent [<a href="#rid8">8,45</a>]. </p><p class="headingAnchor" id="H3096494374"><span class="h2">Chloroquine resistance</span><span class="headingEndMark"> — </span>In most malaria-endemic countries, <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> is the first-line blood schizonticidal agent for all non-falciparum malarias. However, chloroquine resistance (defined as persistent parasitemia after three days of chloroquine therapy or recurrent parasitemia within 28 days following chloroquine therapy) has been documented in the setting of <em>P. vivax</em> infection. </p><p>Chloroquine-resistant <em>P. vivax</em> (CRPV) was first reported from the island of New Guinea (including Papua New Guinea and Papua, Indonesia) in the early 1990s [<a href="#rid46">46-48</a>]. This area remains the epicenter of <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> resistance; clinical trials have demonstrated that more than 60 percent of patients treated with chloroquine in this region have early recurrent infection, with a high proportion requiring hospitalization [<a href="#rid49">49,50</a>]. High levels of treatment failure have also been reported from Sabah, Malaysia and south Sumatra, Indonesia [<a href="#rid51">51,52</a>]. There is also evidence of CRPV to a lesser degree in most <em>P. vivax</em>-endemic countries [<a href="#rid53">53</a>]. Additional information regarding regions with reduced chloroquine efficacy may be found on the website of the Worldwide Antimalarial Resistance Network [<a href="#rid54">54</a>]. </p><p>There has been one report of <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> failure in patients with infection due to <em>P. malariae</em>, although this may reflect inadequate drug absorption rather than drug resistance [<a href="#rid55">55</a>]. Prolonged clearance time for <em>P. malariae</em> parasitemia (≥3 days) has been described in some cases and likely reflects the life cycle duration (72 hours) [<a href="#rid56">56</a>]. </p><p class="headingAnchor" id="H7"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Some clinical manifestations are common to all species of non-falciparum malaria (see <a class="local">'Overview'</a> below), and some clinical manifestations are associated with a particular species. (See <a class="local">'By species'</a> below.)</p><p>Relapse can occur in association with <em>P. vivax</em> or <em>P. ovale </em>infection (see <a class="local">'Relapse'</a> below), and hyper-reactive malarial splenomegaly (HMS) is a complication of chronic malaria (see <a class="local">'Hyper-reactive splenomegaly'</a> below).</p><p class="headingAnchor" id="H1913660804"><span class="h2">Overview</span><span class="headingEndMark"> — </span>The incubation periods among the non-falciparum malarias typically range from 8 to 30 days. Nonimmune patients usually develop an acute febrile illness, and most will have daily episodes of spiking fever over several hours. Semi-immune individuals may present with low-grade fever, may be asymptomatic, or may present with illness in the absence of fever. In semi-immune individuals, the interval between febrile episodes may reflect the duration of the reproductive cycle of the infecting species (<em>P. falciparum, P. vivax,</em> and <em>P. ovale</em>: 48 hours [tertian]; <em>P. malariae</em>: 72 hours [quartan])  (<a class="graphic graphic_figure graphicRef70176" href="/z/d/graphic/70176.html" rel="external">figure 1</a>). In <em>P. knowlesi</em>, the reproductive cycle duration is 24 hours. (See  <a class="medical medical_review" href="/z/d/html/112633.html" rel="external">"Non-falciparum malaria: Plasmodium knowlesi"</a>.) </p><p>Clinical manifestations of uncomplicated malaria are nonspecific and typically include fever, chills, diaphoresis, headache, fatigue, malaise, myalgia, arthralgia, tachycardia, tachypnea, cough, anorexia, nausea, vomiting, abdominal pain, or diarrhea. Physical findings may include jaundice, splenomegaly, and/or hepatomegaly. Febrile seizures may occur in the setting of uncomplicated malaria.</p><p>Clinical manifestations of severe malaria may occur with any malaria species, in the presence or absence of coinfection with <em>P. falciparum </em> (<a class="graphic graphic_table graphicRef107439" href="/z/d/graphic/107439.html" rel="external">table 2</a>) [<a href="#rid6">6</a>]. These manifestations include hemodynamic instability, pulmonary edema, hemolysis, severe anemia, coagulopathy, hypoglycemia, metabolic acidosis, renal failure, hepatic dysfunction, altered mental status, focal neurological deficits, and seizures [<a href="#rid57">57</a>].</p><p class="headingAnchor" id="H600000324"><span class="h2">By species</span><span class="headingEndMark"> — </span>In addition to the above manifestations, some clinical syndromes are associated with a particular malaria species.</p><p class="headingAnchor" id="H760406136"><span class="h3">P. vivax and P. ovale</span><span class="headingEndMark"> — </span>The life cycles of <em>P. vivax</em> and <em>P. ovale </em>include a dormant hepatic stage called the hypnozoite. Although these dormant parasites are asymptomatic, they can activate in the weeks, months, or years after the initial infection, causing recurrent illness known as a relapse (rather than a recrudescence or reinfection) [<a href="#rid18">18</a>]. (See <a class="local">'Relapse'</a> below.)</p><p>Uncomplicated infection due to <em>P. vivax</em> in nonimmune patients typically causes nausea, vomiting, high fevers, rigors, and myalgia. The acute symptoms usually subside quickly with treatment but may linger for several days. Without prompt treatment, progression to severe manifestations can occur, including anemia, disseminated intravascular coagulation, thrombocytopenia, and acute lung injury [<a href="#rid2">2,3,58-60</a>]. Hemodynamic instability, hepatic failure, renal failure, and coma have also been described [<a href="#rid28">28,61</a>]. Splenic rupture or infarct is an unusual but serious complication of <em>P. vivax</em> infection [<a href="#rid62">62-64</a>]. High rates of sepsis in patients presenting with severe <em>P. vivax</em> malaria have been reported [<a href="#rid4">4,65</a>].</p><p><em>P. vivax</em> occurs in tropical and temperate latitudes, and these strains exhibit distinct relapse behaviors. The more prevalent tropical form causes malaria that relapses within three weeks of onset of the primary attack, and then at approximately six- to eight-week intervals thereafter (unless slowly eliminated antimalarial drugs are given, in which case the first relapse is delayed to five to seven weeks after treatment). The majority of relapses in tropical strains occur within six months, but heavily infected patients or patients with prolonged exposure may continue relapsing up to two years and rarely up to four years or more. The temperate form may have an incubation period of up to nine months before relapse after its primary infection and a similarly long interval between subsequent relapses [<a href="#rid19">19</a>].</p><p>Reports of severe <em>P. ovale</em> malaria are uncommon; this likely reflects the relative rarity of <em>P. ovale</em> infection [<a href="#rid6">6</a>]. Splenic rupture, thrombocytopenia, and disseminated intravascular coagulation have been associated with <em>P. ovale</em> infection [<a href="#rid7">7,66-69</a>].</p><p class="headingAnchor" id="H511192898"><span class="h3">P. malariae</span><span class="headingEndMark"> — </span>Malaria due to <em>P. malariae</em> typically causes a relatively mild illness with relatively low parasitemia. However, low-level asymptomatic infection can persist for months or years and the associated anemia can be severe and result in significant mortality [<a href="#rid3">3,45</a>]. In addition, <em>P. malariae</em> may be associated with recurrence even decades after exposure; the mechanism of persistence is unknown [<a href="#rid44">44</a>].</p><p>Chronic <em>P. malariae</em> infection in children has been associated with nephrotic syndrome due to a mixed immunoglobulin (Ig)M and IgG basement membrane immune complex nephropathy [<a href="#rid70">70-73</a>]; one study noted the risk of this complication of 1 in 200 children &lt;5 years of age [<a href="#rid45">45</a>]. Most patients die within two years of this diagnosis, although cure has been described with early recognition and prompt treatment with antimalarial and glucocorticoid therapy [<a href="#rid74">74-77</a>].</p><p><em>P. knowlesi</em> may be misdiagnosed as <em>P. malariae</em> microscopically. (See  <a class="medical medical_review" href="/z/d/html/112633.html" rel="external">"Non-falciparum malaria: Plasmodium knowlesi", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H1215777709"><span class="h2">Relapse</span><span class="headingEndMark"> — </span>The life cycles of <em>P. vivax</em> and <em>P. ovale </em>include hypnozoites, which are dormant stages in the liver that can activate and cause relapse weeks, months, or years after the initial infection  (<a class="graphic graphic_figure graphicRef70176" href="/z/d/graphic/70176.html" rel="external">figure 1</a>) [<a href="#rid18">18</a>]. The presence of hypnozoites in the liver is not associated with clinical symptoms, and available diagnostic tools cannot detect these latent parasites. Relapse occurs with onset of similar symptoms as in a primary attack. Relapse may also occur in the absence of a primary attack; this typically occurs in individuals who have taken malaria prophylaxis during travel in endemic areas [<a href="#rid78">78,79</a>]. At the northernmost reaches of <em>P. vivax</em> endemicity, some strains do not cause a primary attack, but first appear as relapses eight months or more after infection [<a href="#rid19">19</a>].</p><p>The character of relapses varies with geography of transmission [<a href="#rid80">80</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>For malaria strains acquired in most tropical areas, the risk of relapse exceeds 80 percent; first relapses typically occur 21 to 30 days after the initial symptomatic illness. Four or more relapses may occur at approximately two-month intervals [<a href="#rid81">81</a>]. As many as 10 to 20 relapses within two years have been described (in heavily exposed American soldiers repatriated from the Southwestern Pacific theater of World War II).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For malaria strains acquired in temperate areas, the risk of relapse is often &lt;30 percent; relapses usually occur 6 to 12 months after infection, typically with fewer than three relapses occurring in the subsequent months [<a href="#rid19">19</a>]. In tropical India, <em>P. vivax</em> seems to behave more like temperate strains [<a href="#rid82">82</a>], likely due to the monsoonal seasonality of malaria transmission.</p><p></p><p>The timing of hypnozoite activation appears to depend on the seasonal abundance of Anopheline mosquitoes. The long latency of temperate strains coincides with the reappearance of Anopheline mosquitoes after a long winter and spring or with onset of monsoons after a prolonged dry period that is inhospitable to Anopheline mosquitoes. Extrinsic triggers for activation have been hypothesized [<a href="#rid83">83,84</a>]. In malaria-endemic areas, patients undergoing splenectomy have a high risk of <em>P. vivax</em> parasitemia, which is hypothesized to arise from a large reservoir of viable parasites accumulated in the spleen and displaced into the peripheral circulation [<a href="#rid85">85,86</a>].</p><p>Few studies have reported clinical details of relapses due to <em>P. ovale</em>. Most reports describe relapse within 17 to 255 days, although one report describes relapse four years following infection [<a href="#rid87">87-89</a>]. The risk of relapse with <em>P. ovale</em> is lower than with <em>P. vivax </em>malaria. In a retrospective report of returning travelers in Sweden, relapse rates following antimalarial treatment (in the absence of antirelapse treatment with <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a>) were 33 versus 10 percent, respectively [<a href="#rid90">90</a>]. In a study from Gabon, the risk of recurrence within 12 months was higher among patients with <em>P. ovale curtisi</em> than among those with <em>P. ovale wallikeri</em> (61 versus 19 percent); however, it was not possible to confirm whether these cases represented reinfection or true relapse [<a href="#rid91">91</a>]. </p><p>Relapse may be prevented by administration of presumptive anti-relapse therapy that targets hypnozoites. The temperate form of hypnozoites tend to be more sensitive to <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> than the tropical form. (See <a class="local">'Preventing relapse'</a> below.)</p><p class="headingAnchor" id="H13"><span class="h2">Hyper-reactive splenomegaly</span><span class="headingEndMark"> — </span>HMS, previously known as tropical splenomegaly syndrome, is a complication of chronic malaria. The prevalence is high in eastern Indonesia and the Papuan highlands where <em>P. vivax</em> and <em>P. malariae</em> are the predominant species, although it can occur in association with any malaria species [<a href="#rid92">92-95</a>].</p><p>HMS is due to an overproduction of IgM secondary to repeated infection, with subsequent formation of immune complexes that cause prolonged stimulation of splenic reticuloendothelial cells. Among patients in Indonesia with HMS and elevated <em>P. vivax</em> antibody titers, antibody overproduction has been linked to a decrease in T-suppressor lymphocytes that normally downregulate B-lymphocyte function and antibody production [<a href="#rid96">96</a>].</p><p>Clinical manifestations of HMS include left upper quadrant pain, fatigue, ascites, lower extremity edema, and dyspnea; these symptoms become more severe as the disease progresses [<a href="#rid97">97</a>]. Parasitemia is uncommon; the diagnosis is generally made among long-term residents of malarious areas who have massive splenomegaly, high serum antimalarial antibody levels, and polyclonal IgM hypergammaglobulinemia. Diagnosis is based on a constellation of clinical, epidemiological, hematological, and immunological findings [<a href="#rid98">98</a>].</p><p>Management of HMS is discussed below. (See <a class="local">'Hyper-reactive splenomegaly'</a> below.)</p><p class="headingAnchor" id="H15"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Malaria should be suspected in the setting of any febrile illness after exposure in a region where malaria is endemic [<a href="#rid99">99,100</a>]. The diagnosis is established by blood smear microscopy or rapid diagnostic test (RDT). Polymerase chain reaction (PCR) diagnostics can also be used, although they remain primarily tools of research in most locations.</p><p>Microscopic examination of Giemsa-stained blood smears is the traditional method for diagnosis of malaria. This technique allows determination of species identity, quantification of parasitemia, and the life cycle stages present  (<a class="graphic graphic_figure graphicRef80296" href="/z/d/graphic/80296.html" rel="external">figure 2</a> and <a class="graphic graphic_table graphicRef53291" href="/z/d/graphic/53291.html" rel="external">table 1</a>). The limit of detection of microscopy is about 25 parasites/microL in expert hands. Previously malaria-naïve individuals can develop acute symptoms at low-level parasitemia below the limit of detection of microscopy [<a href="#rid101">101</a>]. Hence, even if microscopic examination is negative, it should be repeated at least twice over the course of two days if malaria is suspected. Competent microscopy requires ongoing training, certification, specific supplies, and a properly maintained light microscope capable of 1000x oil immersion magnification.</p><p>RDTs are straightforward to use and interpret and do not require specialized laboratory skills or equipment. However, RDTs have a limit of detection &gt;100 to 200 parasites/microL and do not allow determination of parasitemia or life cycle stages present. Ideally, RDTs should complement standard microscopic examinations of Giemsa-stained blood films if possible. Identification of the species depends on the type of RDT and may be limited to <em>P. falciparum</em> only, <em>P. falciparum </em>versus non-falciparum species (not specified), or <em>P. falciparum</em> versus <em>P. vivax</em>, depending on the RDT used. A systematic review evaluating RDTs for <em>P. vivax</em> demonstrated sensitivity and specificity of 77 to 99 percent and &gt;95 percent, respectively [<a href="#rid102">102</a>]. </p><p>There are no RDTs for definitive diagnosis of <em>P. malariae, P. ovale, </em>or<em> P. knowlesi. </em>Fewer studies have investigated the performance of RDTs for these species; those that have suggest<em> </em>sensitivities of 14 to 80 percent, 20 to 100 percent, and &lt;50 percent, respectively [<a href="#rid103">103</a>].</p><p>PCR diagnosis typically detects as low as 1 parasite/microL. PCR diagnosis with a negative RDT may be useful where competent malaria microscopy is not available.</p><p><em>P. knowlesi</em> appears morphologically similar to <em>P. malariae</em> by microscopy; molecular diagnostic procedures are required for confirmation of <em>P. knowlesi</em> infection [<a href="#rid104">104</a>]. (See  <a class="medical medical_review" href="/z/d/html/112633.html" rel="external">"Non-falciparum malaria: Plasmodium knowlesi", section on 'Diagnosis'</a>.)</p><p>Mixed infections represent a diagnostic challenge, as microscopists may miss detection of an additional species. Some RDTs can detect multiple species (such as pf-HRP2/pan-pLDH and pf-HRP2/aldolase). In some cases, molecular diagnostics may be needed to definitively exclude falciparum malaria, however, access to such tools may not be available in all locations. (See <a class="local">'Mixed infection'</a> below.)</p><p>Additional evaluation should include:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count (evaluating for severe anemia, thrombocytopenia) [<a href="#rid105">105</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Coagulopathy screen </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Liver function testing, including fractionated bilirubin (evaluating for hepatitis, hemolysis)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Basic metabolic panel (evaluating for renal failure, metabolic acidosis, hypoglycemia)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Blood and urine cultures [<a href="#rid4">4,65</a>]</p><p></p><p>Instances of <em>P. vivax</em> infection of bone marrow in the absence of detectable parasitemia have been reported [<a href="#rid106">106-108</a>]. In one case series including 108 patients in India with fever and anemia, thrombocytopenia, or pancytopenia, <em>P. vivax</em> infection of bone marrow was observed in 43 percent of cases [<a href="#rid109">109</a>]. </p><p>Issues related to diagnosis of malaria are discussed further separately. (See  <a class="medical medical_review" href="/z/d/html/5707.html" rel="external">"Laboratory tools for diagnosis of malaria"</a>.)</p><p class="headingAnchor" id="H16"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H697280631"><span class="h2">Uncomplicated infection</span><span class="headingEndMark"> — </span>Uncomplicated malaria consists of symptomatic infection, in the absence of symptoms and signs consistent with severe malaria  (<a class="graphic graphic_table graphicRef107439" href="/z/d/graphic/107439.html" rel="external">table 2</a>).</p><p>If the infecting species is not known with certainty, treatment for uncomplicated <em>P. falciparum</em> should be administered. All patients with mixed infections that include <em>P. falciparum</em> should receive definitive treatment for <em>P. falciparum</em>. (See <a class="local">'Mixed infection'</a> below and  <a class="medical medical_review" href="/z/d/html/5704.html" rel="external">"Treatment of uncomplicated falciparum malaria in nonpregnant adults and children"</a> and  <a class="medical medical_review" href="/z/d/html/4812.html" rel="external">"Malaria in pregnancy: Prevention and treatment"</a>.)</p><p class="headingAnchor" id="H2909789414"><span class="h3">Antimalarial selection</span><span class="headingEndMark"> — </span>Treatment of non-falciparum malaria consists of treating the erythrocytic asexual stages that cause symptomatic illness  (<a class="graphic graphic_figure graphicRef70176" href="/z/d/graphic/70176.html" rel="external">figure 1</a> and <a class="graphic graphic_algorithm graphicRef107988" href="/z/d/graphic/107988.html" rel="external">algorithm 1</a>). In addition, treatment of infections caused by <em>P. vivax</em> and <em>P. ovale</em> requires eradication of liver hypnozoites to prevent clinical attacks caused by relapse. (See <a class="local">'Preventing relapse'</a> below.)</p><p class="headingAnchor" id="H1074782758"><span class="h4">Chloroquine-sensitive infection</span><span class="headingEndMark"> — </span>Treatment of acute non-falciparum malaria consists of <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> or an artemisinin combination therapy (ACT) [<a href="#rid57">57,110</a>]. Dosing is summarized in the table  (<a class="graphic graphic_table graphicRef107829" href="/z/d/graphic/107829.html" rel="external">table 3</a>).</p><p>We use the regimen endorsed by the WHO (and most malaria-endemic countries) consisting of a total dose of 25 mg base/kg orally administered over 3 days in 3 doses (10 mg base/kg on day 1, 10 mg base/kg on day 2; and 5 mg base/kg orally on day 3) [<a href="#rid110">110</a>]. Our approach differs from the CDC guidance which consists of a total dose of 25 mg base/kg orally administered over 3 days in 4 doses (10 mg base/kg initial dose, followed by 5 mg base/kg at 6, 24, and 48 hours) [<a href="#rid111">111</a>]. </p><p><a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">Chloroquine</a> is highly effective against erythrocytic stages of chloroquine-sensitive <em>P. vivax</em>,<em> P. malariae,</em> and <em>P. ovale </em>[<a href="#rid112">112</a>]. In a meta-analysis including 5240 patients with <em>P. vivax</em> malaria, the three-dose chloroquine regimen was well tolerated; when administered as monotherapy, it resulted in 90 percent of patients being recurrence free at 28 days (which rose to 98.6 percent being recurrence free when chloroquine was co-administered with <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a>) [<a href="#rid113">113</a>]. In addition, a higher total dose of chloroquine (30 mg/kg) was associated with a 40 percent lower risk of early recurrence in children &lt;5 years old. Further studies are in progress to confirm whether a higher dose should be used in young children. </p><p>Minor side effects of <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> (including bitter taste, gastrointestinal disturbances, dizziness, blurred vision, and headache) may be alleviated by taking the drug with food. (See  <a class="medical medical_review" href="/z/d/html/468.html" rel="external">"Antimalarial drugs: An overview"</a>.) </p><p>ACTs are also effective against non-falciparum malaria species and advocated by WHO in areas of <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> resistance. Those containing the partner drugs piperaquine, <a class="drug drug_general" data-topicid="9602" href="/z/d/drug information/9602.html" rel="external">mefloquine</a>, or lumefantrine are favored; artesunate-amodiaquine and pyronaridine-artesunate are also likely to be effective and useful in some regions; however, there have been few clinical trials for use of these ACTs for treatment of non-falciparum malaria [<a href="#rid1">1,54</a>]. </p><p>In a systematic review including 14 trials and more than 2500 participants, ACTs were at least equivalent to <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> at treating the blood stage of <em>P. vivax</em> infection [<a href="#rid114">114</a>]. Dihydroartemisinin-piperaquine is the most studied ACT for treatment of non-falciparum malaria; it may provide a longer period of post-treatment suppressive prophylaxis (against untreated relapse) than <a class="drug drug_general" data-topicid="9066" href="/z/d/drug information/9066.html" rel="external">artemether-lumefantrine</a> or artesunate-amodiaquine [<a href="#rid115">115</a>]. Resistance has compromised the efficacy of artesunate-sulfadoxine-pyrimethamine, and this agent is not an appropriate regimen for treatment of non-falciparum malaria [<a href="#rid57">57</a>]. Dosing for ACTs is summarized in the table  (<a class="graphic graphic_table graphicRef107830" href="/z/d/graphic/107830.html" rel="external">table 4</a>).</p><p>Other agents with activity against non-falciparum malaria include <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a> (for chloroquine-sensitive malaria), <a class="drug drug_general" data-topicid="8704" href="/z/d/drug information/8704.html" rel="external">atovaquone-proguanil</a>, <a class="drug drug_general" data-topicid="9602" href="/z/d/drug information/9602.html" rel="external">mefloquine</a>, or a combination of <a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">quinine</a> plus <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> or <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>  (<a class="graphic graphic_table graphicRef107829" href="/z/d/graphic/107829.html" rel="external">table 3</a>) [<a href="#rid116">116-121</a>].</p><p>The sexual stages (gametocytes) of non-falciparum malaria species are susceptible to all schizonticidal antimalarial compounds (including <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> and ACTs); hence, no additional therapy against gametocytes is required to reduce the risk of onward transmission. (See  <a class="medical medical_review" href="/z/d/html/5704.html" rel="external">"Treatment of uncomplicated falciparum malaria in nonpregnant adults and children", section on 'Reducing transmissibility'</a>.)</p><p class="headingAnchor" id="H19"><span class="h4">Chloroquine-resistant infection</span><span class="headingEndMark"> — </span>Chloroquine-resistant <em>P. vivax</em> has been reported at varying frequencies and degrees of severity in almost all endemic regions. (See <a class="local">'Chloroquine resistance'</a> above.)</p><p><a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">Chloroquine</a> resistance is defined as persistent <em>P. vivax</em> parasitemia after three days of chloroquine therapy or recurrent parasitemia within 28 days following chloroquine therapy with adequate drug concentrations (defined as &gt;100 ng/mL whole blood concentrations of chloroquine plus its metabolite desethylchloroquine) [<a href="#rid47">47</a>].</p><p><a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">Chloroquine</a> resistance is difficult to diagnose, since recurrent parasitemia may be due to recrudescent infection (treatment failure and appearance of the same parasite strain), relapse, or reinfection [<a href="#rid122">122</a>]. (See <a class="local">'Recurrent infection'</a> below.)</p><p>In areas of low-grade <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> resistance (eg, less than 10 percent <em>P. vivax</em> recurrence by day 28 post-treatment), patients may be treated with chloroquine plus a course of <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> or <a class="drug drug_general" data-topicid="118521" href="/z/d/drug information/118521.html" rel="external">tafenoquine</a> for prevention of relapse [<a href="#rid53">53,123</a>] (see <a class="local">'Preventing relapse'</a> below). Primaquine also has effective blood schizonticidal effects against <em>P. vivax</em> [<a href="#rid124">124</a>]. However, some countries favor a universal policy of treating all patients with uncomplicated malaria due to any <em>Plasmodia</em> species with an ACT [<a href="#rid125">125</a>]. </p><p>In areas of highly chloroquine-resistant non-falciparum malaria, the preferred treatment regimen consists of ACT plus a course of <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> for prevention of relapse  (<a class="graphic graphic_table graphicRef107830" href="/z/d/graphic/107830.html" rel="external">table 4</a>) [<a href="#rid51">51,110,126-130</a>]. </p><p>Other agents with activity against chloroquine-resistant non-falciparum malaria include<em> </em><a class="drug drug_general" data-topicid="8704" href="/z/d/drug information/8704.html" rel="external">atovaquone-proguanil</a>, <a class="drug drug_general" data-topicid="9602" href="/z/d/drug information/9602.html" rel="external">mefloquine</a>, or a combination of <a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">quinine</a> plus <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> or <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>  (<a class="graphic graphic_table graphicRef107829" href="/z/d/graphic/107829.html" rel="external">table 3</a>) [<a href="#rid124">124,131,132</a>].</p><p class="headingAnchor" id="H3579616738"><span class="h4">Mixed infection</span><span class="headingEndMark"> — </span>Patients with mixed infections that include <em>P. falciparum</em> should receive definitive treatment for <em>P. falciparum</em>. In areas where both <em>P. vivax</em> and <em>P. falciparum</em> are endemic and species diagnosis is not reliable, a regimen with activity against both falciparum and non-falciparum malaria (such as an ACT) should be administered. (See  <a class="medical medical_review" href="/z/d/html/5704.html" rel="external">"Treatment of uncomplicated falciparum malaria in nonpregnant adults and children"</a>.)</p><p><a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">Primaquine</a> should also be administered to patients with <em>P. vivax </em>or <em>P. ovale</em> infection to prevent relapse (in the absence of glucose-6-phosphate dehydrogenase [G6PD] deficiency) [<a href="#rid57">57</a>]. (See <a class="local">'Preventing relapse'</a> below.)</p><p class="headingAnchor" id="H20"><span class="h3">Preventing relapse</span></p><p class="headingAnchor" id="H3977082382"><span class="h4">Clinical approach</span><span class="headingEndMark"> — </span>Presumptive anti-relapse therapy is required to eradicate the dormant hypnozoite liver stages of <em>P. vivax</em> and <em>P. ovale</em> and prevent relapses  (<a class="graphic graphic_figure graphicRef70176" href="/z/d/graphic/70176.html" rel="external">figure 1</a>) [<a href="#rid57">57,133,134</a>]. (See <a class="local">'Relapse'</a> above.)</p><p>The available drugs are <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> and <a class="drug drug_general" data-topicid="118521" href="/z/d/drug information/118521.html" rel="external">tafenoquine</a>; both are 8-aminoquinoline compounds which can induce acute hemolysis in individuals with G6PD deficiency [<a href="#rid135">135,136</a>]. For this reason, patients should undergo G6PD screening prior to administration of anti-relapse therapy. (See <a class="local">'G6PD screening'</a> below.)</p><p>Antirelapse treatment is administered in combination with appropriate antimalarial therapy for <em>P. vivax</em> or <em>P. ovale </em>asexual stage infection (such as <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> or an ACT) (see <a class="local">'Antimalarial selection'</a> above). Our approach to <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> dosing is as follows  (<a class="graphic graphic_table graphicRef130538" href="/z/d/graphic/130538.html" rel="external">table 5</a>) (see <a class="local">'Primaquine'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>G6PD enzyme activity ≥30 percent</strong> − For nonpregnant individuals &gt;6 months of age with G6PD enzyme activity ≥30 percent (using a quantitative assay) or ‘normal’ G6PD status (using a qualitative assay), we dose <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> as follows: 0.5 mg/kg daily over 14 days (total dose 7 mg/kg), coadministered with appropriate antimalarial therapy for<em> </em>asexual stage infection. This regimen prevents relapses of <em>P. vivax</em> acquired from all endemic areas [<a href="#rid133">133,137-139</a>], and has a greater efficacy than the lower dose regimen (total dose 3.5 mg/kg) which is recommended in most endemic countries where G6PD enzyme screening is not available [<a href="#rid140">140</a>].</p><p></p><p class="bulletIndent1">For nonpregnant individuals ≥16 years of age with G6PD enzyme activity &gt;70 percent (using a quantitative assay) [<a href="#rid141">141</a>], an alternative approach consists of <a class="drug drug_general" data-topicid="118521" href="/z/d/drug information/118521.html" rel="external">tafenoquine</a> (300 mg single dose). In addition, a dispersible formulation is licensed for children &gt;2 years of age in Australia but not in the United States [<a href="#rid142">142</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="118521" href="/z/d/drug information/118521.html" rel="external">Tafenoquine</a> should be reserved for patients with concerns over adherence to a 14-day <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> regimen, since tafenoquine has lower efficacy than primaquine in areas of high-relapse periodicity [<a href="#rid143">143</a>]. In addition, tafenoquine should only be used in combination with <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> (eg, not ACT) [<a href="#rid143">143</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>G6PD enzyme activity &lt;30 percent</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For nonpregnant G6PD-deficient individuals &gt;6 months of age with G6PD activity &lt;30 percent, we administer a modified <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> regimen as follows: 0.75 mg base/kg once weekly for eight weeks (total dose 6 mg/kg), with close monitoring for hemolysis [<a href="#rid57">57,110</a>]; however, safety and efficacy data for this regimen are limited [<a href="#rid57">57,144-146</a>]. (See  <a class="medical medical_review" href="/z/d/html/7111.html" rel="external">"Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who are ineligible for <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> or <a class="drug drug_general" data-topicid="118521" href="/z/d/drug information/118521.html" rel="external">tafenoquine</a> therapy (including pregnant patients, patients &lt;6 months of age, or patients with prior severe reaction to these drugs), counseling regarding the possibility of relapsing infection should be provided, including guidance to seek repeat treatment if symptoms recur [<a href="#rid147">147</a>]. </p><p></p><p class="bulletIndent2">No radical cure regimens have been validated for use in these individuals; <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> prophylaxis (300 mg base weekly for six months) may be administered, although late relapses may still occur [<a href="#rid116">116</a>]. In the setting of chloroquine-resistant <em>P. vivax</em>, <a class="drug drug_general" data-topicid="9602" href="/z/d/drug information/9602.html" rel="external">mefloquine</a> prophylaxis (228 mg base weekly) may be used. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unknown G6PD status</strong> − For patients with unknown G6PD status, we dose <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> as follows: 0.25 mg/kg daily over 14 days (total dose 3.5 mg/kg), with close monitoring to minimize the risk of drug-induced hemolysis [<a href="#rid148">148</a>]. This lower dose regimen is sufficient for preventing <em>P. ovale</em> relapse and may be sufficient for preventing <em>P. vivax</em> relapse for infection<em> </em>acquired in areas of lower relapse periodicity [<a href="#rid57">57,133,149</a>]. However, in areas with high-relapse periodicity, it may have poor efficacy [<a href="#rid140">140,150</a>]. </p><p></p><p>Hypnozoitocidal drugs can cause gastrointestinal upset when taken without food. If the patient is able to tolerate a light snack or meal, then hypnozoitocidal therapy may be coadministered with blood schizontocidal therapy. If not, hypnozoitocidal therapy should be initiated once normal oral intake can be resumed. </p><p>Patients treated with <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> or <a class="drug drug_general" data-topicid="118521" href="/z/d/drug information/118521.html" rel="external">tafenoquine</a> should be monitored for clinically significant hemolysis; hemoglobinuria, jaundice, or dyspnea should prompt treatment discontinuation.</p><p>Hypnozoitocidal drugs can also cause methemoglobinemia; this is rarely of clinical concern and is usually self-limiting. (See  <a class="medical medical_review" href="/z/d/html/7094.html" rel="external">"Methemoglobinemia"</a>.)</p><p class="headingAnchor" id="H660360949"><span class="h4">G6PD screening</span><span class="headingEndMark"> — </span>G6PD testing should be performed prior to administration of anti-relapse therapy with <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> or <a class="drug drug_general" data-topicid="118521" href="/z/d/drug information/118521.html" rel="external">tafenoquine</a>. While a modified primaquine dosing regimen may be administered in the absence of G6PD test results, G6PD testing is compulsory prior to use of tafenoquine. (See <a class="local">'Clinical approach'</a> above.)</p><p>G6PD enzyme activity can be assessed by quantitative or qualitative tests. Qualitative G6PD screening produces a binary reading that can reliably detect individuals with enzyme activity less than 30 percent of normal. The most commonly used qualitative assay test is the fluorescent spot test. There are also commercially available G6PD test kits for use with a capillary or venous blood sample that render an easily read color change within 10 minutes [<a href="#rid151">151</a>]. (See  <a class="medical medical_review" href="/z/d/html/7111.html" rel="external">"Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency"</a>.)</p><p>G6PD deficiency is an X-linked enzymopathy in which almost all hemizygous males and homozygous females have residual enzyme activity below 30 percent and so can be reliably detected using a qualitative assay. However, female heterozygotes with mosaicism for the trait can have intermediate enzyme activity (30 to 70 percent) and thus screen as G6PD-normal by the qualitative test [<a href="#rid152">152,153</a>]. Heterozygous females with intermediate G6PD activity may have significant hemolysis when treated with <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> or <a class="drug drug_general" data-topicid="118521" href="/z/d/drug information/118521.html" rel="external">tafenoquine</a> [<a href="#rid154">154</a>].</p><p class="headingAnchor" id="H707998792"><span class="h4">Antirelapse agents</span></p><p class="headingAnchor" id="H1123348498"><span class="h5">Primaquine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">Primaquine</a> dosing is discussed above. (See <a class="local">'Clinical approach'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> − <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">Primaquine</a> is the antirelapse agent for which there is greatest clinical experience; it has been used for decades [<a href="#rid155">155</a>]. It is contraindicated in G6PD-deficient individuals, pregnant women (since the G6PD status of the fetus cannot be determined), and infants &lt;6 months of age. In addition, primaquine is not recommended in lactating women who are breastfeeding infants &lt;6 months old. One report found very low concentrations of primaquine in breast milk after 28 days postpartum, suggesting administration of primaquine to lactating women may be safe for the infant [<a href="#rid156">156</a>]; further studies are needed. (See  <a class="medical medical_review" href="/z/d/html/4812.html" rel="external">"Malaria in pregnancy: Prevention and treatment", section on 'Non-falciparum malaria'</a>.)</p><p></p><p class="bulletIndent1">The main determinant of <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> efficacy is the total dose administered  (<a class="graphic graphic_table graphicRef130538" href="/z/d/graphic/130538.html" rel="external">table 5</a>) [<a href="#rid155">155</a>]. The duration is usually spread over 14 days to reduce the risks of acute drug-induced hemolysis and gastrointestinal discomfort [<a href="#rid110">110</a>]. Gastrointestinal symptoms can be reduced by administering the drug with food [<a href="#rid155">155,157</a>]. Adherence may be diminished after resolution of symptoms; therefore, patients should be educated on the importance of completing a full course of treatment [<a href="#rid158">158-160</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rationale for use of high-dose </strong><strong>primaquine</strong><strong> </strong>− Given marked heterogeneity in the risk and timing of relapse in different regions and patient populations [<a href="#rid155">155</a>], we favor high-dose <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> (total dose 7 mg/kg rather than 3.5 mg/kg) administered over 14 days; this approach provides more reliable antirelapse efficacy and is preferred in patients who are not G6PD deficient [<a href="#rid140">140</a>]. Our approach differs from the 2022 World Health Organization (WHO) guidance [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1">The WHO guidance varies by region and accommodates the frequent lack of G6PD testing in remote malaria endemic areas. In most regions, the WHO recommends lower dose <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> (3.5 mg/kg, administered as 0.25 mg/kg/day over 14 days or 0.5 mg/kg/day over 7 days), whereas in East Asia and Oceania, the WHO recommends higher dose primaquine (7 mg/kg, usually administered as 0.5 mg/kg/day over 14 days) [<a href="#rid1">1</a>]. </p><p></p><p class="bulletIndent1">A 2020 systematic review noted no difference in recurrence rates or adverse events with 3.5 mg/kg versus 7 mg/kg over 14 days, although only two randomized controlled trials were included in the comparison of these regimens [<a href="#rid139">139</a>]. In a subsequent randomized trial including 254 Brazilian patients ≥5 years of age with nonsevere <em>P. vivax</em> malaria, patients received initial treatment with <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> and then were randomly assigned to treatment with low-dose <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> (3.5 mg/kg; 0.5 mg/kg for 7 days) or high-dose primaquine 7 mg/kg (0.5 mg/kg for 14 days) [<a href="#rid150">150</a>]. Those who received high-dose primaquine were more likely to reach the 24-week follow-up with no recurrence (86 versus 58 percent). </p><p></p><p class="bulletIndent1">Similarly, in a meta-analysis including 36 trials and 8589 patients with <em>P. vivax</em> malaria, the risk of recurrent infection was lower after treatment with high-dose <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> compared with the low-dose primaquine (adjusted hazard ratio [AHR] 0.45, 95% CI 0.34-0.60); this was apparent both in areas of East Asia and Oceania (AHR 0.55) and other endemic regions (AHR 0.42) [<a href="#rid140">140</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use of shorter-course </strong><strong>primaquine</strong><strong> regimens</strong> − Shorter-course regimens with a higher daily dose may improve adherence to a complete course of treatment. In G6PD normal patients (≥30 percent G6PD activity), the efficacy of a 7-day high dose <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> regimen (1 mg/kg per day) has been shown to be non-inferior to a 14-day regimen (0.5 mg/kg per day) [<a href="#rid137">137,138,161</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a randomized trial including 2336 G6PD-normal patients enrolled in Afghanistan, Ethiopia, Indonesia, and Vietnam, rates of recurrent vivax malaria for the 7-day regimen and the 14-day regimen were 0.18 and 0.16 episodes per person-year, respectively [<a href="#rid138">138</a>]. Adverse events were observed more frequently in the group treated for 7 days (1.0 versus 0.1 percent), but most were generally mild, self-limited, and of short duration. There were nine related serious adverse events in the 7-day regimen (five due to gastrointestinal intolerance, three due to hemolysis, and one due to methemoglobinemia) compared with only one in the 14-day regimen.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Similarly, in a randomized trial including 680 G6PD-normal patients on the Thailand-Myanmar border, recurrence rates for the 7-day regimen and the 14-day regimen were comparable (12 percent with no difference between groups) [<a href="#rid137">137</a>]. Both regimens were generally well tolerated; however, two heterozygous women (undetected by qualitative screening) had clinically significant hemolysis. </p><p></p><p class="headingAnchor" id="H3331233928"><span class="h5">Tafenoquine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="118521" href="/z/d/drug information/118521.html" rel="external">Tafenoquine</a> was approved by the US Food and Drug Administration in 2018 for preventing relapse of <em>P. vivax </em>infection in nonpregnant individuals ≥16 years of age. Approval in Australia was expanded in 2022 for children ≥2 years of age. The antirelapse efficacy of tafenoquine likely extends to <em>P. ovale</em>, in view of the biologic similarities between <em>P. vivax</em> and <em>P. ovale</em> and the supposed good efficacy of <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> for prevention of <em>P. ovale </em>relapse<em> </em>[<a href="#rid162">162</a>].</p><p>The efficacy of <a class="drug drug_general" data-topicid="118521" href="/z/d/drug information/118521.html" rel="external">tafenoquine</a> (single dose) for relapse prevention is supported by data from randomized trials [<a href="#rid135">135,163-165</a>]. In the Dose and Efficacy Trial Evaluating <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">Chloroquine</a> and Tafenoquine in Vivax Elimination (DETECTIVE), a randomized trial including more than 500 patients that evaluated the efficacy of chloroquine plus tafenoquine (300 mg single dose) or chloroquine plus placebo in patients with phenotypically normal G6PD activity, chloroquine plus tafenoquine proved more efficacious than chloroquine plus placebo for prevention of <em>P. vivax</em> malaria relapse (62 versus 28 percent) during the six months following therapy [<a href="#rid163">163,164</a>]. </p><p>A meta-analysis of the data from DETECTIVE [<a href="#rid164">164</a>] and another trial, Global Assessment of <a class="drug drug_general" data-topicid="118521" href="/z/d/drug information/118521.html" rel="external">Tafenoquine</a> Hemolytic Risk (GATHER) [<a href="#rid165">165</a>], compared the efficacy of tafenoquine (300 mg single dose) and <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> (15 mg once daily for 14 days) for preventing recurrence of <em>P. vivax</em> malaria. The risk of relapse at six months was nonsignificantly higher after tafenoquine compared with primaquine (33 versus 27 percent), with an odds ratio of 1.81 (95% CI 0.82-3.96) [<a href="#rid165">165</a>].</p><p>The GATHER trial also evaluated hemolysis associated with <a class="drug drug_general" data-topicid="118521" href="/z/d/drug information/118521.html" rel="external">tafenoquine</a> and <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> [<a href="#rid165">165</a>]. Among patients with normal (&gt;70 percent) G6PD enzyme activity phenotype, there was no significant difference in the decline in hemoglobin level between the groups (2.4 versus 1.2 percent).</p><p>Administration of <a class="drug drug_general" data-topicid="118521" href="/z/d/drug information/118521.html" rel="external">tafenoquine</a> in the licensing studies was restricted to patients with &gt;70 percent G6PD enzyme activity [<a href="#rid164">164,165</a>]. For this reason, the manufacturers advise against administering tafenoquine unless a quantitative G6PD measurement is performed with the ability to identify patients with &gt;70 percent G6PD enzyme activity. A quantitative point-of-care assay has been developed to support tafenoquine implementation [<a href="#rid166">166</a>].</p><p><a class="drug drug_general" data-topicid="118521" href="/z/d/drug information/118521.html" rel="external">Tafenoquine</a> use for radical cure should only be used in patients receiving <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> against acute <em>P. vivax</em> infection; it cannot be used with other antimalarials due to concerns about reduced antirelapse efficacy [<a href="#rid167">167</a>]. Thus, if ACT is used to treat <em>P. vivax</em>, then <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> should be used for radical cure [<a href="#rid168">168</a>].</p><p class="headingAnchor" id="H21"><span class="h3">Monitoring and follow-up</span><span class="headingEndMark"> — </span>With appropriate treatment, fever and parasitemia usually resolve within two to four days; this may vary depending on strain differences, host factors, and type of antimalarial therapy. Serial blood smears should be performed after initiation of treatment until parasitemia is no longer detectable. In general, following <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> treatment, the parasite density should be lower than 25 percent of the pretreatment density by day 3 and undetectable by day 4. The speed of the parasite clearance (assessed by microscopy) has been proposed as a marker of parasite susceptibility; parasite clearance in 95 percent of patients by day 2 or all patients by day 3 is 100 percent predictive of chloroquine sensitivity [<a href="#rid53">53</a>]. (See  <a class="medical medical_review" href="/z/d/html/5709.html" rel="external">"Malaria: Clinical manifestations and diagnosis in nonpregnant adults and children"</a>.)</p><p>Patients with normal G6PD activity may have a significant decline in hemoglobin, attributable to parasite-induced hemolysis. Patients with decreased G6PD activity may also have a significant decline in hemoglobin, attributable to parasite and/or drug-induced hemolysis [<a href="#rid141">141,169</a>]. Repeat testing should be performed on days 7 and 28 following initiation of therapy to confirm cure and hematologic recovery, even in the absence of symptoms. Recurrent fever over the ensuing six months may signal recurrent infection and<em> </em>should prompt repeat evaluation with blood smear.</p><p class="headingAnchor" id="H153652559"><span class="h2">Severe infection</span><span class="headingEndMark"> — </span>Patients with severe malaria should be treated for presumed <em>P. falciparum</em> infection, regardless of species diagnosis  (<a class="graphic graphic_table graphicRef107439" href="/z/d/graphic/107439.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/5667.html" rel="external">"Treatment of severe malaria"</a>.)</p><p>Severe non-falciparum malaria refers to malaria infection caused by a non-falciparum species associated with manifestations such as hemodynamic instability, pulmonary edema, hemolysis, severe anemia, coagulopathy, hypoglycemia, metabolic acidosis, renal failure, hepatic dysfunction, altered mental status, focal neurological deficits, or seizures [<a href="#rid57">57</a>].</p><p class="headingAnchor" id="H2740129559"><span class="h2">Recurrent infection</span></p><p class="headingAnchor" id="H4228774604"><span class="h3">Causes</span><span class="headingEndMark"> — </span>Recurrent infection can result from recrudescence, relapse, or reinfection; these may be difficult to distinguish:</p><p class="bulletIndent1"><span class="glyph">●</span>Recrudescence (failed schizonticidal therapy) refers to the re-emergence of blood stage forms following reduction of parasitemia and resolution of clinical symptoms yet incomplete clearance of infection; it generally occurs within six to nine weeks after an initial infection [<a href="#rid170">170</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Relapse refers to reactivation of liver hypnozoites weeks to months after the initial treatment; if hypnozoitocidal treatment was administered, it represents failed hypnozoitocidal therapy. Relapses account for 66 to 95 percent of all recurrent vivax malaria episodes [<a href="#rid21">21</a>]. (See <a class="local">'Impaired primaquine metabolism'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reinfection refers to new infection transmitted via mosquito exposure.</p><p></p><p>Patients with recurrent infection should be treated promptly with an alternate agent. Options include ACT, <a class="drug drug_general" data-topicid="8704" href="/z/d/drug information/8704.html" rel="external">atovaquone-proguanil</a>, <a class="drug drug_general" data-topicid="9602" href="/z/d/drug information/9602.html" rel="external">mefloquine</a>, or <a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">quinine</a> plus <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> (or <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>). Antimalarial selection should be individualized based on local resistance patterns where the infection was acquired.</p><p class="headingAnchor" id="H1951742396"><span class="h3">Impaired primaquine metabolism</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">Primaquine</a> is a prodrug metabolized by cytochrome P450 isozyme 2D6 (CYP2D6) to derivatives that kill parasites attempting hepatic development [<a href="#rid171">171</a>]. Patients who have experienced relapses following directly observed high-dose primaquine therapy have been found to have genotypes of CYP2D6 associated with impaired primaquine metabolism [<a href="#rid172">172</a>]. </p><p>For this reason, patients who relapse following <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> therapy with adequate dosing and good adherence should be evaluated for CYP2D6 genotype, with categorization of the predicted activity phenotypes (null, intermediate, normal, or ultra-metabolizer) [<a href="#rid173">173</a>]. Null metabolizers are unlikely to benefit from even high doses of primaquine, whereas others may benefit from an escalated dosing regimen.</p><p>In a case-control study nested within a clinical trial of <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> (high-dose directly observed therapy) against <em>P. vivax</em> relapse in 177 individuals, 21 of 26 therapeutic failures (cases) were evaluated for CYP2D6 genotype and <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">dextromethorphan</a> metabolism phenotype (along with 36 randomly selected controls who did not relapse) [<a href="#rid174">174</a>]; 20 of those 21 cases had impaired CYP2D6 genotypes and phenotypes compared with relatively few controls (odds ratio 18, 95% CI 2.2-148). </p><p>Impaired CYP2D6 metabolism has not been associated with increased risk of relapses following treatment with <a class="drug drug_general" data-topicid="118521" href="/z/d/drug information/118521.html" rel="external">tafenoquine</a> [<a href="#rid175">175</a>].</p><p class="headingAnchor" id="H3447025753"><span class="h2">Hyper-reactive splenomegaly</span><span class="headingEndMark"> — </span>Clinical manifestations of hyper-reactive splenomegaly are described above. (See <a class="local">'Hyper-reactive splenomegaly'</a> above.)</p><p>Treatment of hyper-reactive splenomegaly consists of antimalarial therapy for the duration of ongoing malaria exposure. <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">Chloroquine</a> (300 mg base [= 500 mg salt]) once weekly is effective in reducing spleen size and symptoms over several months in 70 to 80 percent of cases [<a href="#rid93">93,97</a>]. In areas with known chloroquine resistance, alternative agents should be used at full dose for initial treatment followed by prophylactic doses at intermittent intervals. Splenectomy carries an appreciable risk of mortality and so should only be considered as a treatment for severely debilitating massive splenomegaly unresponsive to medical management [<a href="#rid93">93,176</a>].</p><p class="headingAnchor" id="H1200357325"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113035.html" rel="external">"Society guideline links: Malaria"</a>.)</p><p class="headingAnchor" id="H24"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Non-falciparum malaria</strong> − Non-falciparum malaria refers to malaria infection due to <em>Plasmodium</em> species other than <em>P. falciparum</em>; these include <em>P. vivax</em>, <em>P. ovale</em>, <em>P. malariae</em>, and <em>P. knowlesi </em> (<a class="graphic graphic_table graphicRef53291" href="/z/d/graphic/53291.html" rel="external">table 1</a>).<em> P. vivax</em> is the most common non-falciparum malaria species; approximately one-third of the world's population is at risk for infection caused by this species. Infections caused by<em> P. knowlesi</em> and <em>P. vivax</em> are associated with significant risk of morbidity and mortality; severe disease due to <em>P. malariae</em> and <em>P. ovale</em> is less common. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – The incubation periods of the non-falciparum malarias are 8 to 30 days. Clinical manifestations of uncomplicated malaria include fever, chills, headache, fatigue, malaise, myalgia, and other symptoms. Clinical manifestations of severe malaria include hemodynamic instability, severe anemia, metabolic acidosis, renal failure, altered mental status, and other symptoms. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relapse</strong> − The life cycles of <em>P. vivax</em> and <em>P. ovale </em>include hypnozoites, which are dormant stages in the liver that can reactivate weeks, months, or years after the initial infection, causing relapse. (See <a class="local">'Relapse'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> − Malaria should be suspected in the setting of febrile illness after exposure to a region where malaria is endemic. The diagnosis is established by blood smear microscopy or rapid diagnostic test. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antimalarial selection</strong> </p><p></p><p class="bulletIndent2"><strong>General principles</strong> − Treatment of uncomplicated non-falciparum malaria consists of treating the erythrocytic forms  (<a class="graphic graphic_figure graphicRef70176" href="/z/d/graphic/70176.html" rel="external">figure 1</a> and <a class="graphic graphic_algorithm graphicRef107988" href="/z/d/graphic/107988.html" rel="external">algorithm 1</a>). If the infecting species is not known with certainty, treatment for uncomplicat<em>ed P. falciparum</em> should be administered. Patients with mixed infections that inclu<em>de P. falciparum</em> should receive definitive treatment f<em>or P. falciparum</em>. Patients with severe malaria should be treated for presumed seve<em>re P. falciparum</em> infection, regardless of species diagnosis  (<a class="graphic graphic_table graphicRef107439" href="/z/d/graphic/107439.html" rel="external">table 2</a>). (See <a class="local">'Antimalarial selection'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Chloroquine-sensitive infection</strong> − We suggest treating chloroquine-sensitive non-falciparum malaria with <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> or artemisinin combination therapy (ACT) (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Dosing is summarized in the tables  (<a class="graphic graphic_table graphicRef107830" href="/z/d/graphic/107830.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef107829" href="/z/d/graphic/107829.html" rel="external">table 3</a>). (See <a class="local">'Chloroquine-sensitive infection'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Chloroquine-resistant infection</strong> − A high prevalence of <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> resistance has been associated wi<em>th P. vivax</em> infection in southeastern Asia and Oceania; it is defined as persiste<em>nt P. vivax</em> parasitemia after three days of chloroquine therapy or recurrent parasitemia within 28 days following chloroquine therapy. We suggest treating chloroquine-resistant non-falciparum malaria with an ACT (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>)  (<a class="graphic graphic_table graphicRef107830" href="/z/d/graphic/107830.html" rel="external">table 4</a>). (See <a class="local">'Chloroquine resistance'</a> above and <a class="local">'Chloroquine-resistant infection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antirelapse therapy</strong> − We recommend presumptive antirelapse therapy to eradicate the hypnozoite liver stages of <em>P. vivax</em> and <em>P. ovale</em> (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>). Such treatment can be started after symptoms have begun to subside and normal glucose-6-phosphate dehydrogenase (G6PD) status has been confirmed. Antirelapse therapy dosing is summarized in the table  (<a class="graphic graphic_table graphicRef130538" href="/z/d/graphic/130538.html" rel="external">table 5</a>). </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>G6PD enzyme activity ≥30 percent</strong> − For patients with G6PD enzyme activity ≥30 percent (using a quantitative assay) or ‘normal’ G6PD status (using a qualitative assay), we dose <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> as follows: 0.5 mg/kg daily over 14 days (total dose 7 mg/kg), coadministered with appropriate antimalarial therapy for<em> </em>asexual stage infection. </p><p></p><p class="bulletIndent3">An alternative approach for nonpregnant individuals ≥16 years of age with G6PD enzyme activity &gt;70 percent (using a quantitative assay) who received <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> consists of <a class="drug drug_general" data-topicid="118521" href="/z/d/drug information/118521.html" rel="external">tafenoquine</a> (300 mg single dose). In countries where the dispersible formulation is licensed, tafenoquine can also be used in children &gt;2 years of age (weight-based dosing). Tafenoquine should be reserved for patients with concerns over adherence to a 14-day <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> regimen, since tafenoquine has lower efficacy than primaquine in areas of high-relapse periodicity.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>G6PD enzyme activity &lt;30 percent</strong> − For nonpregnant G6PD-deficient individuals &gt;6 months of age with G6PD activity &lt;30 percent, we administer a modified <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> regimen as follows: 0.75 mg base/kg once weekly for eight weeks (total dose 6 mg/kg). Primaquine administration should be combined with careful supervision for hemolysis, particularly in the first week.</p><p></p><p class="bulletIndent3">For patients who are not eligible for antirelapse therapy (including pregnant patients, patients &lt;6 months of age, or patients with prior severe reaction to these drugs), counseling regarding the possibility of relapsing infection should be provided, including guidance to seek repeat treatment if symptoms recur.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Unknown G6PD status</strong> − For patients with unknown G6PD status in whom G6PD testing is not available, we dose <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> as follows: 0.25 mg/kg daily over 14 days (total dose 3.5 mg/kg), to minimize the risk of drug-induced hemolysis. This lower dose regimen is sufficient for preventing <em>P. ovale</em> relapse and may be sufficient for preventing <em>P. vivax</em> relapse for infection<em> </em>acquired in areas of lower relapse periodicity. However, in areas with high-relapse periodicity, it may have poor efficacy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring and follow-up</strong> − With appropriate treatment, fever and parasitemia usually resolve within two to four days. Daily smears should be performed until parasitemia is no longer detectable. Repeat testing on days 7 and 28 following initiation of therapy is warranted to confirm hematologic recovery and cure, even in the absence of symptoms. (See <a class="local">'Monitoring and follow-up'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recurrent infection</strong> − Recurrent infection after therapy may result from recrudescence (failed schizontocidal therapy), relapse (failed hypnozoitocidal therapy), or reinfection; these may be difficult to distinguish. Failed hypnozoitocidal therapy following <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> may be due to impaired CYP2D6 metabolism of primaquine. (See <a class="local">'Recurrent infection'</a> above.)</p><p></p><p class="headingAnchor" id="H5023674"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Jason Maguire, MD, and J Kevin Baird, PhD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">World Health Organization. Guidelines for malaria, 25 November 2022. https://www.who.int/publications/i/item/guidelines-for-malaria (Accessed on January 23, 2022).</li><li><a class="nounderline abstract_t">Baird JK. Evidence and implications of mortality associated with acute Plasmodium vivax malaria. Clin Microbiol Rev 2013; 26:36.</a></li><li><a class="nounderline abstract_t">Douglas NM, Lampah DA, Kenangalem E, et al. Major burden of severe anemia from non-falciparum malaria species in Southern Papua: a hospital-based surveillance study. PLoS Med 2013; 10:e1001575; discussion e1001575.</a></li><li><a class="nounderline abstract_t">Douglas NM, Pontororing GJ, Lampah DA, et al. Mortality attributable to Plasmodium vivax malaria: a clinical audit from Papua, Indonesia. BMC Med 2014; 12:217.</a></li><li><a class="nounderline abstract_t">Tomar LR, Giri S, Bauddh NK, Jhamb R. Complicated malaria: a rare presentation of Plasmodium ovale. Trop Doct 2015; 45:140.</a></li><li><a class="nounderline abstract_t">Hwang J, Cullen KA, Kachur SP, et al. Severe morbidity and mortality risk from malaria in the United States, 1985-2011. Open Forum Infect Dis 2014; 1:ofu034.</a></li><li><a class="nounderline abstract_t">Kotepui M, Kotepui KU, Milanez GD, Masangkay FR. Severity and mortality of severe Plasmodium ovale infection: A systematic review and meta-analysis. PLoS One 2020; 15:e0235014.</a></li><li><a class="nounderline abstract_t">Kotepui M, Kotepui KU, Milanez GD, Masangkay FR. Global prevalence and mortality of severe Plasmodium malariae infection: a systematic review and meta-analysis. Malar J 2020; 19:274.</a></li><li class="breakAll">World Health Organization. World malaria report 2022. https://www.who.int/publications/i/item/world-malaria-report-2022 (Accessed on March 15, 2023).</li><li><a class="nounderline abstract_t">Battle KE, Lucas TCD, Nguyen M, et al. Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000-17: a spatial and temporal modelling study. Lancet 2019; 394:332.</a></li><li class="breakAll">World Health Organization. World malaria report 2019. https://www.who.int/publications/i/item/world-malaria-report-2019 (Accessed on November 13, 2020).</li><li><a class="nounderline abstract_t">Twohig KA, Pfeffer DA, Baird JK, et al. Growing evidence of Plasmodium vivax across malaria-endemic Africa. PLoS Negl Trop Dis 2019; 13:e0007140.</a></li><li><a class="nounderline abstract_t">Price RN, Commons RJ, Battle KE, et al. Plasmodium vivax in the Era of the Shrinking P. falciparum Map. Trends Parasitol 2020; 36:560.</a></li><li><a class="nounderline abstract_t">Broderick C, Nadjm B, Smith V, et al. Clinical, geographical, and temporal risk factors associated with presentation and outcome of vivax malaria imported into the United Kingdom over 27 years: observational study. BMJ 2015; 350:h1703.</a></li><li><a class="nounderline abstract_t">Robert LL, Santos-Ciminera PD, Andre RG, et al. Plasmodium-infected Anopheles mosquitoes collected in Virginia and Maryland following local transmission of Plasmodium vivax malaria in Loudoun County, Virginia. J Am Mosq Control Assoc 2005; 21:187.</a></li><li><a class="nounderline abstract_t">Andriopoulos P, Economopoulou A, Spanakos G, Assimakopoulos G. A local outbreak of autochthonous Plasmodium vivax malaria in Laconia, Greece--a re-emerging infection in the southern borders of Europe? Int J Infect Dis 2013; 17:e125.</a></li><li><a class="nounderline abstract_t">Blackburn D, Drennon M, Broussard K, et al. Outbreak of Locally Acquired Mosquito-Transmitted (Autochthonous) Malaria - Florida and Texas, May-July 2023. MMWR Morb Mortal Wkly Rep 2023; 72:973.</a></li><li><a class="nounderline abstract_t">White NJ, Imwong M. Relapse. Adv Parasitol 2012; 80:113.</a></li><li><a class="nounderline abstract_t">White NJ. Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J 2011; 10:297.</a></li><li><a class="nounderline abstract_t">White MT, Walker P, Karl S, et al. Mathematical modelling of the impact of expanding levels of malaria control interventions on Plasmodium vivax. Nat Commun 2018; 9:3300.</a></li><li><a class="nounderline abstract_t">Commons RJ, Simpson JA, Watson J, et al. Estimating the Proportion of Plasmodium vivax Recurrences Caused by Relapse: A Systematic Review and Meta-Analysis. Am J Trop Med Hyg 2020; 103:1094.</a></li><li><a class="nounderline abstract_t">Ménard D, Barnadas C, Bouchier C, et al. Plasmodium vivax clinical malaria is commonly observed in Duffy-negative Malagasy people. Proc Natl Acad Sci U S A 2010; 107:5967.</a></li><li><a class="nounderline abstract_t">Mendes C, Dias F, Figueiredo J, et al. Duffy negative antigen is no longer a barrier to Plasmodium vivax--molecular evidences from the African West Coast (Angola and Equatorial Guinea). PLoS Negl Trop Dis 2011; 5:e1192.</a></li><li><a class="nounderline abstract_t">Wurtz N, Mint Lekweiry K, Bogreau H, et al. Vivax malaria in Mauritania includes infection of a Duffy-negative individual. Malar J 2011; 10:336.</a></li><li><a class="nounderline abstract_t">Culleton R, Ndounga M, Zeyrek FY, et al. Evidence for the transmission of Plasmodium vivax in the Republic of the Congo, West Central Africa. J Infect Dis 2009; 200:1465.</a></li><li><a class="nounderline abstract_t">Bernabeu M, Gomez-Perez GP, Sissoko S, et al. Plasmodium vivax malaria in Mali: a study from three different regions. Malar J 2012; 11:405.</a></li><li><a class="nounderline abstract_t">Dini S, Douglas NM, Poespoprodjo JR, et al. The risk of morbidity and mortality following recurrent malaria in Papua, Indonesia: a retrospective cohort study. BMC Med 2020; 18:28.</a></li><li><a class="nounderline abstract_t">Kochar DK, Saxena V, Singh N, et al. Plasmodium vivax malaria. Emerg Infect Dis 2005; 11:132.</a></li><li><a class="nounderline abstract_t">Tjitra E, Anstey NM, Sugiarto P, et al. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med 2008; 5:e128.</a></li><li><a class="nounderline abstract_t">Barcus MJ, Basri H, Picarima H, et al. Demographic risk factors for severe and fatal vivax and falciparum malaria among hospital admissions in northeastern Indonesian Papua. Am J Trop Med Hyg 2007; 77:984.</a></li><li><a class="nounderline abstract_t">Nurleila S, Syafruddin D, Elyazar IR, Baird JK. Serious and fatal illness associated with falciparum and vivax malaria among patients admitted to hospital at West Sumba in eastern Indonesia. Am J Trop Med Hyg 2012; 87:41.</a></li><li><a class="nounderline abstract_t">Kochar DK, Das A, Kochar A, et al. A prospective study on adult patients of severe malaria caused by Plasmodium falciparum, Plasmodium vivax and mixed infection from Bikaner, northwest India. J Vector Borne Dis 2014; 51:200.</a></li><li><a class="nounderline abstract_t">Alexandre MA, Ferreira CO, Siqueira AM, et al. Severe Plasmodium vivax malaria, Brazilian Amazon. Emerg Infect Dis 2010; 16:1611.</a></li><li><a class="nounderline abstract_t">Poespoprodjo JR, Fobia W, Kenangalem E, et al. Vivax malaria: a major cause of morbidity in early infancy. Clin Infect Dis 2009; 48:1704.</a></li><li><a class="nounderline abstract_t">McGready R, Lee SJ, Wiladphaingern J, et al. Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study. Lancet Infect Dis 2012; 12:388.</a></li><li><a class="nounderline abstract_t">Maguire JD, Fenton ME, Susanti AI, Walker JB. Plasmodium vivax-associated acute respiratory distress syndrome after extended travel in Afghanistan. Travel Med Infect Dis 2007; 5:301.</a></li><li><a class="nounderline abstract_t">Kotwal RS, Wenzel RB, Sterling RA, et al. An outbreak of malaria in US Army Rangers returning from Afghanistan. JAMA 2005; 293:212.</a></li><li><a class="nounderline abstract_t">Kawamoto F, Liu Q, Ferreira MU, Tantular IS. How prevalent are Plasmodium ovale and P. malariae in East Asia? Parasitol Today 1999; 15:422.</a></li><li><a class="nounderline abstract_t">Baird JK, Purnomo, Masbar S. Plasmodium ovale in Indonesia. Southeast Asian J Trop Med Public Health 1990; 21:541.</a></li><li><a class="nounderline abstract_t">Sutherland CJ, Tanomsing N, Nolder D, et al. Two nonrecombining sympatric forms of the human malaria parasite Plasmodium ovale occur globally. J Infect Dis 2010; 201:1544.</a></li><li><a class="nounderline abstract_t">Hawadak J, Dongang Nana RR, Singh V. Global trend of Plasmodium malariae and Plasmodium ovale spp. malaria infections in the last two decades (2000-2020): a systematic review and meta-analysis. Parasit Vectors 2021; 14:297.</a></li><li><a class="nounderline abstract_t">Mueller I, Zimmerman PA, Reeder JC. Plasmodium malariae and Plasmodium ovale--the "bashful" malaria parasites. Trends Parasitol 2007; 23:278.</a></li><li><a class="nounderline abstract_t">Yavne Y, Leshem E, Paran Y, et al. Plasmodium malariae in Israeli Travelers: A Nationwide Study. Clin Infect Dis 2017; 65:1516.</a></li><li><a class="nounderline abstract_t">Morovic M, Poljak I, Miletic B, et al. Late symptomatic Plasmodium malariae relapse in the territory of the former Yugoslavia. J Travel Med 2003; 10:301.</a></li><li><a class="nounderline abstract_t">Langford S, Douglas NM, Lampah DA, et al. Plasmodium malariae Infection Associated with a High Burden of Anemia: A Hospital-Based Surveillance Study. PLoS Negl Trop Dis 2015; 9:e0004195.</a></li><li><a class="nounderline abstract_t">Baird JK. Chloroquine resistance in Plasmodium vivax. Antimicrob Agents Chemother 2004; 48:4075.</a></li><li><a class="nounderline abstract_t">Baird JK, Leksana B, Masbar S, et al. Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. Am J Trop Med Hyg 1997; 56:621.</a></li><li><a class="nounderline abstract_t">Rieckmann KH, Davis DR, Hutton DC. Plasmodium vivax resistance to chloroquine? Lancet 1989; 2:1183.</a></li><li><a class="nounderline abstract_t">Sumawinata IW, Bernadeta, Leksana B, et al. Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua. Am J Trop Med Hyg 2003; 68:416.</a></li><li><a class="nounderline abstract_t">Ratcliff A, Siswantoro H, Kenangalem E, et al. Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia. Trans R Soc Trop Med Hyg 2007; 101:351.</a></li><li><a class="nounderline abstract_t">Grigg MJ, William T, Menon J, et al. Efficacy of Artesunate-mefloquine for Chloroquine-resistant Plasmodium vivax Malaria in Malaysia: An Open-label, Randomized, Controlled Trial. Clin Infect Dis 2016; 62:1403.</a></li><li><a class="nounderline abstract_t">Sutanto I, Endawati D, Ling LH, et al. Evaluation of chloroquine therapy for vivax and falciparum malaria in southern Sumatra, western Indonesia. Malar J 2010; 9:52.</a></li><li><a class="nounderline abstract_t">Price RN, von Seidlein L, Valecha N, et al. Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis. Lancet Infect Dis 2014; 14:982.</a></li><li class="breakAll">Worldwide Antimalarial Resistance Network. Vivax Surveyor. http://www.wwarn.org/vivax/surveyor/#0 (Accessed on December 01, 2020).</li><li><a class="nounderline abstract_t">Maguire JD, Sumawinata IW, Masbar S, et al. Chloroquine-resistant Plasmodium malariae in south Sumatra, Indonesia. Lancet 2002; 360:58.</a></li><li><a class="nounderline abstract_t">Betson M, Sousa-Figueiredo JC, Atuhaire A, et al. Detection of persistent Plasmodium spp. infections in Ugandan children after artemether-lumefantrine treatment. Parasitology 2014; 141:1880.</a></li><li class="breakAll">Guidelines for the Treatment of Malaria, World Health Organization, Geneva 2015.</li><li><a class="nounderline abstract_t">Anstey NM, Douglas NM, Poespoprodjo JR, Price RN. Plasmodium vivax: clinical spectrum, risk factors and pathogenesis. Adv Parasitol 2012; 80:151.</a></li><li><a class="nounderline abstract_t">Douglas NM, Anstey NM, Buffet PA, et al. The anaemia of Plasmodium vivax malaria. Malar J 2012; 11:135.</a></li><li><a class="nounderline abstract_t">Barber BE, William T, Grigg MJ, et al. Parasite biomass-related inflammation, endothelial activation, microvascular dysfunction and disease severity in vivax malaria. PLoS Pathog 2015; 11:e1004558.</a></li><li><a class="nounderline abstract_t">Lampah DA, Yeo TW, Malloy M, et al. Severe malarial thrombocytopenia: a risk factor for mortality in Papua, Indonesia. J Infect Dis 2015; 211:623.</a></li><li><a class="nounderline abstract_t">LUBITZ JM. Pathology of the ruptured spleen in acute vivax malaria. Blood 1949; 4:1168.</a></li><li><a class="nounderline abstract_t">Gockel HR, Heidemann J, Lorenz D, Gockel I. Spontaneous splenic rupture, in tertian malaria. Infection 2006; 34:43.</a></li><li><a class="nounderline abstract_t">Jiménez BC, Navarro M, Huerga H, López-Vélez R. Spontaneous splenic rupture due to Plasmodium vivax in a traveler: case report and review. J Travel Med 2007; 14:188.</a></li><li><a class="nounderline abstract_t">Bhattacharya SK, Sur D, Dutta S, et al. Vivax malaria and bacteraemia: a prospective study in Kolkata, India. Malar J 2013; 12:176.</a></li><li><a class="nounderline abstract_t">Facer CA, Rouse D. Spontaneous splenic rupture due to Plasmodium ovale malaria. Lancet 1991; 338:896.</a></li><li><a class="nounderline abstract_t">Moudden MK, Boukhira A, Zyani M, et al. [Severe imported malaria: the experience of the Avicenna military hospital of Marrakech]. Sante 2006; 16:259.</a></li><li><a class="nounderline abstract_t">Davis TM, Singh B, Sheridan G. Parasitic procrastination: late-presenting ovale malaria and schistosomiasis. Med J Aust 2001; 175:146.</a></li><li><a class="nounderline abstract_t">Miyashita N, Karino T, Nagatomo Y, et al. [A case of Plasmodium ovale malaria with thrombocytopenia and an abnormality grade in FDP concentration despite the use of chloroquine as a malaria prophylaxis]. Kansenshogaku Zasshi 1995; 69:450.</a></li><li><a class="nounderline abstract_t">GILLES HM, HENDRICKSE RG. Possible aetiological role of Plasmodium malariae in "nephrotic syndrome" in Nigerian children. Lancet 1960; 1:806.</a></li><li><a class="nounderline abstract_t">Abdurrahman MB, Greenwood BM, Narayana P, et al. Immunological aspects of nephrotic syndrome in northern Nigeria. Arch Dis Child 1981; 56:199.</a></li><li><a class="nounderline abstract_t">Abdurrahman MB, Aikhionbare HA, Babaoye FA, et al. Clinicopathological features of childhood nephrotic syndrome in northern Nigeria. Q J Med 1990; 75:563.</a></li><li><a class="nounderline abstract_t">Vinetz JM, Li J, McCutchan TF, Kaslow DC. Plasmodium malariae infection in an asymptomatic 74-year-old Greek woman with splenomegaly. N Engl J Med 1998; 338:367.</a></li><li><a class="nounderline abstract_t">Michaud E, Ninet J, Coppère B, et al. [Nephrotic syndrome caused by Plasmodium malariae infection. A case with favourable outcome]. Presse Med 1992; 21:1386.</a></li><li><a class="nounderline abstract_t">Anochie I, Eke F, Okpere A. Childhood nephrotic syndrome: change in pattern and response to steroids. J Natl Med Assoc 2006; 98:1977.</a></li><li><a class="nounderline abstract_t">Ehrich JH, Eke FU. Malaria-induced renal damage: facts and myths. Pediatr Nephrol 2007; 22:626.</a></li><li><a class="nounderline abstract_t">Neri S, Pulvirenti D, Patamia I, et al. Acute renal failure in Plasmodium malariae infection. Neth J Med 2008; 66:166.</a></li><li><a class="nounderline abstract_t">Schwartz E, Parise M, Kozarsky P, Cetron M. Delayed onset of malaria--implications for chemoprophylaxis in travelers. N Engl J Med 2003; 349:1510.</a></li><li><a class="nounderline abstract_t">Meltzer E, Rahav G, Schwartz E. Vivax Malaria Chemoprophylaxis: The Role of Atovaquone-Proguanil Compared to Other Options. Clin Infect Dis 2018; 66:1751.</a></li><li><a class="nounderline abstract_t">Battle KE, Karhunen MS, Bhatt S, et al. Geographical variation in Plasmodium vivax relapse. Malar J 2014; 13:144.</a></li><li><a class="nounderline abstract_t">Ingram RJ, Crenna-Darusallam C, Soebianto S, et al. The clinical and public health problem of relapse despite primaquine therapy: case review of repeated relapses of Plasmodium vivax acquired in Papua New Guinea. Malar J 2014; 13:488.</a></li><li><a class="nounderline abstract_t">Joshi H, Prajapati SK, Verma A, et al. Plasmodium vivax in India. Trends Parasitol 2008; 24:228.</a></li><li><a class="nounderline abstract_t">Shanks GD, White NJ. The activation of vivax malaria hypnozoites by infectious diseases. Lancet Infect Dis 2013; 13:900.</a></li><li><a class="nounderline abstract_t">Commons RJ, Simpson JA, Thriemer K, et al. Risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: a systematic review and meta-analysis. Lancet Infect Dis 2019; 19:91.</a></li><li><a class="nounderline abstract_t">Kho S, Andries B, Poespoprodjo JR, et al. High Risk of Plasmodium vivax Malaria Following Splenectomy in Papua, Indonesia. Clin Infect Dis 2019; 68:51.</a></li><li><a class="nounderline abstract_t">Kho S, Qotrunnada L, Leonardo L, et al. Hidden Biomass of Intact Malaria Parasites in the Human Spleen. N Engl J Med 2021; 384:2067.</a></li><li><a class="nounderline abstract_t">Chin W, Coatney GR. Relapse activity in sporozoite-induced infections with a West African strain of Plasmodium ovale. Am J Trop Med Hyg 1971; 20:825.</a></li><li><a class="nounderline abstract_t">Chin W, Contacos PG. A recently isolated West African strain of plasmodium ovale. Am J Trop Med Hyg 1966; 15:1.</a></li><li><a class="nounderline abstract_t">TRAGER W, MOST H. A LONG-DELAYED PRIMARY ATTACK OF OVALE MALARIA. Am J Trop Med Hyg 1963; 12:837.</a></li><li><a class="nounderline abstract_t">Wångdahl A, Sondén K, Wyss K, et al. Relapse of Plasmodium vivax and Plasmodium ovale Malaria With and Without Primaquine Treatment in a Nonendemic Area. Clin Infect Dis 2022; 74:1199.</a></li><li><a class="nounderline abstract_t">Groger M, Veletzky L, Lalremruata A, et al. Prospective Clinical and Molecular Evaluation of Potential Plasmodium ovale curtisi and wallikeri Relapses in a High-transmission Setting. Clin Infect Dis 2019; 69:2119.</a></li><li><a class="nounderline abstract_t">Hoffman SL, Piessens WF, Ratiwayanto S, et al. Reduction of suppressor T lymphocytes in the tropical splenomegaly syndrome. N Engl J Med 1984; 310:337.</a></li><li><a class="nounderline abstract_t">Vriend WH, Hoffman SL, Silaban T, Zaini M. Splenectomy in massive tropical splenomegaly: two-to six-year follow-up in 14 patients. Trop Geogr Med 1988; 40:298.</a></li><li><a class="nounderline abstract_t">Moraes MF, Soares M, Arroz MJ, et al. [New concepts in hyperactive malarial splenomegaly]. Acta Med Port 2003; 16:41.</a></li><li><a class="nounderline abstract_t">Paparello SF, Hoffman SL. Hyperreactive malarial splenomegaly: part I. Postgrad Med 1992; 15:336.</a></li><li><a class="nounderline abstract_t">Mothe B, Lopez-Contreras J, Torres OH, et al. A case of hyper-reactive malarial splenomegaly. The role of rapid antigen-detecting and PCR-based tests. Infection 2008; 36:167.</a></li><li><a class="nounderline abstract_t">Gupta OP, Bajaj S, Gupta SC. A study on tropical splenomegaly syndrome and chloroquine prophylaxis. J Assoc Physicians India 1989; 37:570.</a></li><li><a class="nounderline abstract_t">Fakunle YM. Tropical splenomegaly. Part 1: Tropical Africa. Clin Haematol 1981; 10:963.</a></li><li><a class="nounderline abstract_t">Wilson ME, Weld LH, Boggild A, et al. Fever in returned travelers: results from the GeoSentinel Surveillance Network. Clin Infect Dis 2007; 44:1560.</a></li><li><a class="nounderline abstract_t">Svenson JE, MacLean JD, Gyorkos TW, Keystone J. Imported malaria. Clinical presentation and examination of symptomatic travelers. Arch Intern Med 1995; 155:861.</a></li><li><a class="nounderline abstract_t">Epstein JE, Rao S, Williams F, et al. Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: an update. J Infect Dis 2007; 196:145.</a></li><li><a class="nounderline abstract_t">Agarwal R, Choi L, Johnson S, Takwoingi Y. Rapid diagnostic tests for Plasmodium vivax malaria in endemic countries. Cochrane Database Syst Rev 2020; 11:CD013218.</a></li><li><a class="nounderline abstract_t">Yerlikaya S, Campillo A, Gonzalez IJ. A Systematic Review: Performance of Rapid Diagnostic Tests for the Detection of Plasmodium knowlesi, Plasmodium malariae, and Plasmodium ovale Monoinfections in Human Blood. J Infect Dis 2018; 218:265.</a></li><li><a class="nounderline abstract_t">Roth JM, Korevaar DA, Leeflang MM, Mens PF. Molecular malaria diagnostics: A systematic review and meta-analysis. Crit Rev Clin Lab Sci 2016; 53:87.</a></li><li><a class="nounderline abstract_t">Rodríguez-Morales AJ, Sánchez E, Vargas M, et al. Anemia and thrombocytopenia in children with Plasmodium vivax malaria. J Trop Pediatr 2006; 52:49.</a></li><li><a class="nounderline abstract_t">Imirzalioglu C, Soydan N, Schaller M, et al. Diagnosis of mixed Plasmodium malariae and P. vivax infection in a development aid volunteer by examination of bone-marrow specimens by real-time PCR. J Clin Microbiol 2006; 44:2307.</a></li><li><a class="nounderline abstract_t">Lacerda MV, Hipólito JR, Passos LN. Chronic Plasmodium vivax infection in a patient with splenomegaly and severe thrombocytopenia. Rev Soc Bras Med Trop 2008; 41:522.</a></li><li><a class="nounderline abstract_t">Ru YX, Mao BY, Zhang FK, et al. Invasion of erythroblasts by Pasmodium vivax: A new mechanism contributing to malarial anemia. Ultrastruct Pathol 2009; 33:236.</a></li><li><a class="nounderline abstract_t">Rastogi N, Rehman N. Changes in bone marrow in malaria-a prospective study of 47 cases. International Journal of Research in Medical Sciences 2018; 6.</a></li><li class="breakAll">WHO Guidelines for malaria, 13 July 2021. Geneva: World Health Organization; 2021. https://cdn.who.int/media/docs/default-source/malaria/who-ucn-gmp-2021.01-eng.pdf?sfvrsn=bd30cd9b_10&amp;download=true (Accessed on August 10, 2021).</li><li class="breakAll">https://www.cdc.gov/malaria/resources/pdf/malaria_treatment_table_202302c.pdf (Accessed on January 22, 2024).</li><li><a class="nounderline abstract_t">Siswantoro H, Russell B, Ratcliff A, et al. In vivo and in vitro efficacy of chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia. Antimicrob Agents Chemother 2011; 55:197.</a></li><li><a class="nounderline abstract_t">Commons RJ, Simpson JA, Thriemer K, et al. The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis. Lancet Infect Dis 2018; 18:1025.</a></li><li><a class="nounderline abstract_t">Gogtay N, Kannan S, Thatte UM, et al. Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria. Cochrane Database Syst Rev 2013; :CD008492.</a></li><li><a class="nounderline abstract_t">Commons RJ, Simpson JA, Thriemer K, et al. The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis. PLoS Med 2019; 16:e1002928.</a></li><li><a class="nounderline abstract_t">Griffith KS, Lewis LS, Mali S, Parise ME. Treatment of malaria in the United States: a systematic review. JAMA 2007; 297:2264.</a></li><li><a class="nounderline abstract_t">Ringwald P, Bickii J, Same-Ekobo A, Basco LK. Pyronaridine for treatment of Plasmodium ovale and Plasmodium malariae infections. Antimicrob Agents Chemother 1997; 41:2317.</a></li><li><a class="nounderline abstract_t">Genton B, Baea K, Lorry K, et al. Parasitological and clinical efficacy of standard treatment regimens against Plasmodium falciparum, P. vivax and P. malariae in Papua New Guinea. P N G Med J 2005; 48:141.</a></li><li><a class="nounderline abstract_t">Borrmann S, Szlezák N, Binder RK, et al. Evidence for the efficacy of artesunate in asymptomatic Plasmodium malariae infections. J Antimicrob Chemother 2002; 50:751.</a></li><li><a class="nounderline abstract_t">Awab GR, Pukrittayakamee S, Imwong M, et al. Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial. Malar J 2010; 9:105.</a></li><li><a class="nounderline abstract_t">Phyo AP, Lwin KM, Price RN, et al. Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial. Clin Infect Dis 2011; 53:977.</a></li><li><a class="nounderline abstract_t">Price RN, Auburn S, Marfurt J, Cheng Q. Phenotypic and genotypic characterisation of drug-resistant Plasmodium vivax. Trends Parasitol 2012; 28:522.</a></li><li><a class="nounderline abstract_t">Abreha T, Hwang J, Thriemer K, et al. Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial. PLoS Med 2017; 14:e1002299.</a></li><li><a class="nounderline abstract_t">Pukrittayakamee S, Chantra A, Simpson JA, et al. Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrob Agents Chemother 2000; 44:1680.</a></li><li><a class="nounderline abstract_t">Douglas NM, Anstey NM, Angus BJ, et al. Artemisinin combination therapy for vivax malaria. Lancet Infect Dis 2010; 10:405.</a></li><li><a class="nounderline abstract_t">Ratcliff A, Siswantoro H, Kenangalem E, et al. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet 2007; 369:757.</a></li><li><a class="nounderline abstract_t">Karunajeewa HA, Mueller I, Senn M, et al. A trial of combination antimalarial therapies in children from Papua New Guinea. N Engl J Med 2008; 359:2545.</a></li><li><a class="nounderline abstract_t">Pasaribu AP, Chokejindachai W, Sirivichayakul C, et al. A randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine combined with primaquine for radical treatment of vivax malaria in Sumatera, Indonesia. J Infect Dis 2013; 208:1906.</a></li><li><a class="nounderline abstract_t">Hasugian AR, Purba HL, Kenangalem E, et al. Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clin Infect Dis 2007; 44:1067.</a></li><li><a class="nounderline abstract_t">Siqueira AM, Alencar AC, Melo GC, et al. Fixed-Dose Artesunate-Amodiaquine Combination vs Chloroquine for Treatment of Uncomplicated Blood Stage P. vivax Infection in the Brazilian Amazon: An Open-Label Randomized, Controlled Trial. Clin Infect Dis 2017; 64:166.</a></li><li><a class="nounderline abstract_t">Maguire JD, Krisin, Marwoto H, et al. Mefloquine is highly efficacious against chloroquine-resistant Plasmodium vivax malaria and Plasmodium falciparum malaria in Papua, Indonesia. Clin Infect Dis 2006; 42:1067.</a></li><li><a class="nounderline abstract_t">Lacy MD, Maguire JD, Barcus MJ, et al. Atovaquone/proguanil therapy for Plasmodium falciparum and Plasmodium vivax malaria in Indonesians who lack clinical immunity. Clin Infect Dis 2002; 35:e92.</a></li><li><a class="nounderline abstract_t">John GK, Douglas NM, von Seidlein L, et al. Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malar J 2012; 11:280.</a></li><li><a class="nounderline abstract_t">Galappaththy GN, Tharyan P, Kirubakaran R. Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine. Cochrane Database Syst Rev 2013; :CD004389.</a></li><li><a class="nounderline abstract_t">Rueangweerayut R, Bancone G, Harrell EJ, et al. Hemolytic Potential of Tafenoquine in Female Volunteers Heterozygous for Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency (G6PD Mahidol Variant) versus G6PD-Normal Volunteers. Am J Trop Med Hyg 2017; 97:702.</a></li><li><a class="nounderline abstract_t">Brito-Sousa JD, Santos TC, Avalos S, et al. Clinical Spectrum of Primaquine-induced Hemolysis in Glucose-6-Phosphate Dehydrogenase Deficiency: A 9-Year Hospitalization-based Study From the Brazilian Amazon. Clin Infect Dis 2019; 69:1440.</a></li><li><a class="nounderline abstract_t">Chu CS, Phyo AP, Turner C, et al. Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria. Clin Infect Dis 2019; 68:1311.</a></li><li><a class="nounderline abstract_t">Taylor WRJ, Thriemer K, von Seidlein L, et al. Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. Lancet 2019; 394:929.</a></li><li><a class="nounderline abstract_t">Milligan R, Daher A, Villanueva G, et al. Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax. Cochrane Database Syst Rev 2020; 8:CD012656.</a></li><li><a class="nounderline abstract_t">Commons RJ, Rajasekhar M, Edler P, et al. Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis. Lancet Infect Dis 2023.</a></li><li><a class="nounderline abstract_t">Chu CS, Bancone G, Moore KA, et al. Haemolysis in G6PD Heterozygous Females Treated with Primaquine for Plasmodium vivax Malaria: A Nested Cohort in a Trial of Radical Curative Regimens. PLoS Med 2017; 14:e1002224.</a></li><li><a class="nounderline abstract_t">Vélez ID, Hien TT, Green JA, et al. Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with Plasmodium vivax malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial. Lancet Child Adolesc Health 2022; 6:86.</a></li><li class="breakAll">Therapeutic Goods Administration. AUSTRALIAN PRODUCT INFORMATION.
KOZENIS (TAFENOQUINE) TABLETS. https://www.tga.gov.au/sites/default/files/auspar-tafenoquine-as-succinate-181115-pi.pdf (Accessed on May 19, 2022).</li><li><a class="nounderline abstract_t">Hill DR, Baird JK, Parise ME, et al. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg 2006; 75:402.</a></li><li><a class="nounderline abstract_t">Taylor WRJ, Kheng S, Muth S, et al. Hemolytic Dynamics of Weekly Primaquine Antirelapse Therapy Among Cambodians With Acute Plasmodium vivax Malaria With or Without Glucose-6-Phosphate Dehydrogenase Deficiency. J Infect Dis 2019; 220:1750.</a></li><li><a class="nounderline abstract_t">Taylor WRJ, Meagher N, Ley B, et al. Weekly primaquine for radical cure of patients with Plasmodium vivax malaria and glucose-6-phosphate dehydrogenase deficiency. PLoS Negl Trop Dis 2023; 17:e0011522.</a></li><li><a class="nounderline abstract_t">Baird JK, Hoffman SL. Primaquine therapy for malaria. Clin Infect Dis 2004; 39:1336.</a></li><li><a class="nounderline abstract_t">Rajasekhar M, Simpson JA, Ley B, et al. Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis. Lancet Infect Dis 2023.</a></li><li><a class="nounderline abstract_t">Rijal KR, Adhikari B, Ghimire P, et al. Efficacy of Primaquine in Preventing Short- and Long-Latency Plasmodium vivax Relapses in Nepal. J Infect Dis 2019; 220:448.</a></li><li><a class="nounderline abstract_t">Chamma-Siqueira NN, Negreiros SC, Ballard SB, et al. Higher-Dose Primaquine to Prevent Relapse of Plasmodium vivax Malaria. N Engl J Med 2022; 386:1244.</a></li><li><a class="nounderline abstract_t">Ley B, Luter N, Espino FE, et al. The challenges of introducing routine G6PD testing into radical cure: a workshop report. Malar J 2015; 14:377.</a></li><li><a class="nounderline abstract_t">Thielemans L, Gornsawun G, Hanboonkunupakarn B, et al. Diagnostic performances of the fluorescent spot test for G6PD deficiency in newborns along the Thailand-Myanmar border: A cohort study. Wellcome Open Res 2018; 3:1.</a></li><li><a class="nounderline abstract_t">von Seidlein L, Auburn S, Espino F, et al. Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop report. Malar J 2013; 12:112.</a></li><li><a class="nounderline abstract_t">Chu CS, Hwang J. Tafenoquine: a toxicity overview. Expert Opin Drug Saf 2021; 20:349.</a></li><li><a class="nounderline abstract_t">Baird JK. 8-Aminoquinoline Therapy for Latent Malaria. Clin Microbiol Rev 2019; 32.</a></li><li><a class="nounderline abstract_t">Gilder ME, Hanpithakphong W, Hoglund RM, et al. Primaquine Pharmacokinetics in Lactating Women and Breastfed Infant Exposures. Clin Infect Dis 2018; 67:1000.</a></li><li><a class="nounderline abstract_t">Woon SA, Moore BR, Laman M, et al. Ultra-short course, high-dose primaquine to prevent Plasmodium vivax infection following uncomplicated pediatric malaria: A randomized, open-label, non-inferiority trial of early versus delayed treatment. Int J Infect Dis 2023; 130:189.</a></li><li><a class="nounderline abstract_t">Baird JK, Rieckmann KH. Can primaquine therapy for vivax malaria be improved? Trends Parasitol 2003; 19:115.</a></li><li><a class="nounderline abstract_t">Maneeboonyang W, Lawpoolsri S, Puangsa-Art S, et al. Directly observed therapy with primaquine to reduce the recurrence rate of plasmodium vivax infection along the Thai-Myanmar border. Southeast Asian J Trop Med Public Health 2011; 42:9.</a></li><li><a class="nounderline abstract_t">Douglas NM, Poespoprodjo JR, Patriani D, et al. Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study. PLoS Med 2017; 14:e1002379.</a></li><li><a class="nounderline abstract_t">Milligan R, Daher A, Graves PM. Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria. Cochrane Database Syst Rev 2019; 7:CD012656.</a></li><li><a class="nounderline abstract_t">Haston JC, Hwang J, Tan KR. Guidance for Using Tafenoquine for Prevention and Antirelapse Therapy for Malaria - United States, 2019. MMWR Morb Mortal Wkly Rep 2019; 68:1062.</a></li><li><a class="nounderline abstract_t">Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet 2014; 383:1049.</a></li><li><a class="nounderline abstract_t">Lacerda MVG, Llanos-Cuentas A, Krudsood S, et al. Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria. N Engl J Med 2019; 380:215.</a></li><li><a class="nounderline abstract_t">Llanos-Cuentas A, Lacerda MVG, Hien TT, et al. Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. N Engl J Med 2019; 380:229.</a></li><li><a class="nounderline abstract_t">Ley B, Bancone G, von Seidlein L, et al. Methods for the field evaluation of quantitative G6PD diagnostics: a review. Malar J 2017; 16:361.</a></li><li><a class="nounderline abstract_t">Sutanto I, Soebandrio A, Ekawati LL, et al. Tafenoquine co-administered with dihydroartemisinin-piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study. Lancet Infect Dis 2023; 23:1153.</a></li><li class="breakAll">Clinical update on radical cure of P. vivax. Centers for Disease Control and Prevention, 2022. https://wwwnc.cdc.gov/travel/news-announcements/tafenoquine-malaria-prophylaxis-and-treatment (Accessed on September 05, 2023).</li><li><a class="nounderline abstract_t">Commons RJ, Simpson JA, Thriemer K, et al. The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. BMC Med 2019; 17:151.</a></li><li><a class="nounderline abstract_t">White NJ. The assessment of antimalarial drug efficacy. Trends Parasitol 2002; 18:458.</a></li><li><a class="nounderline abstract_t">Marcsisin SR, Reichard G, Pybus BS. Primaquine pharmacology in the context of CYP 2D6 pharmacogenomics: Current state of the art. Pharmacol Ther 2016; 161:1.</a></li><li><a class="nounderline abstract_t">Bennett JW, Pybus BS, Yadava A, et al. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. N Engl J Med 2013; 369:1381.</a></li><li><a class="nounderline abstract_t">Gaedigk A, Sangkuhl K, Whirl-Carrillo M, et al. Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med 2017; 19:69.</a></li><li><a class="nounderline abstract_t">Baird JK, Louisa M, Noviyanti R, et al. Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for Latent Plasmodium vivax Malaria. JAMA Netw Open 2018; 1:e181449.</a></li><li><a class="nounderline abstract_t">St Jean PL, Xue Z, Carter N, et al. Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial. Malar J 2016; 15:97.</a></li><li><a class="nounderline abstract_t">Leoni S, Buonfrate D, Angheben A, et al. The hyper-reactive malarial splenomegaly: a systematic review of the literature. Malar J 2015; 14:185.</a></li></ol></div><div id="topicVersionRevision">Topic 5706 Version 73.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.who.int/publications/i/item/guidelines-for-malaria" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : World Health Organization. Guidelines for malaria, 25 November 2022. https://www.who.int/publications/i/item/guidelines-for-malaria (Accessed on January 23, 2022).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23297258" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Evidence and implications of mortality associated with acute Plasmodium vivax malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24358031" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Major burden of severe anemia from non-falciparum malaria species in Southern Papua: a hospital-based surveillance study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25406857" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Mortality attributable to Plasmodium vivax malaria: a clinical audit from Papua, Indonesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25672340" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Complicated malaria: a rare presentation of Plasmodium ovale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25734104" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Severe morbidity and mortality risk from malaria in the United States, 1985-2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32559238" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Severity and mortality of severe Plasmodium ovale infection: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32736635" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Global prevalence and mortality of severe Plasmodium malariae infection: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32736635" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Global prevalence and mortality of severe Plasmodium malariae infection: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31229233" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000-17: a spatial and temporal modelling study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31229233" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000-17: a spatial and temporal modelling study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30703083" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Growing evidence of Plasmodium vivax across malaria-endemic Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32407682" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Plasmodium vivax in the Era of the Shrinking P. falciparum Map.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25882309" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Clinical, geographical, and temporal risk factors associated with presentation and outcome of vivax malaria imported into the United Kingdom over 27 years: observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16033121" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Plasmodium-infected Anopheles mosquitoes collected in Virginia and Maryland following local transmission of Plasmodium vivax malaria in Loudoun County, Virginia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23098813" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A local outbreak of autochthonous Plasmodium vivax malaria in Laconia, Greece--a re-emerging infection in the southern borders of Europe?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37676839" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Outbreak of Locally Acquired Mosquito-Transmitted (Autochthonous) Malaria - Florida and Texas, May-July 2023.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23199487" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Relapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21989376" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Determinants of relapse periodicity in Plasmodium vivax malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30120250" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Mathematical modelling of the impact of expanding levels of malaria control interventions on Plasmodium vivax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32524950" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Estimating the Proportion of Plasmodium vivax Recurrences Caused by Relapse: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20231434" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Plasmodium vivax clinical malaria is commonly observed in Duffy-negative Malagasy people.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21713024" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Duffy negative antigen is no longer a barrier to Plasmodium vivax--molecular evidences from the African West Coast (Angola and Equatorial Guinea).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22050867" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Vivax malaria in Mauritania includes infection of a Duffy-negative individual.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19803728" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Evidence for the transmission of Plasmodium vivax in the Republic of the Congo, West Central Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23217064" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Plasmodium vivax malaria in Mali: a study from three different regions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32075649" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The risk of morbidity and mortality following recurrent malaria in Papua, Indonesia: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15705338" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Plasmodium vivax malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18563962" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17984364" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Demographic risk factors for severe and fatal vivax and falciparum malaria among hospital admissions in northeastern Indonesian Papua.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22764290" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Serious and fatal illness associated with falciparum and vivax malaria among patients admitted to hospital at West Sumba in eastern Indonesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25253213" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A prospective study on adult patients of severe malaria caused by Plasmodium falciparum, Plasmodium vivax and mixed infection from Bikaner, northwest India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20875292" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Severe Plasmodium vivax malaria, Brazilian Amazon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19438395" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Vivax malaria: a major cause of morbidity in early infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22169409" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17870635" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Plasmodium vivax-associated acute respiratory distress syndrome after extended travel in Afghanistan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15644548" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : An outbreak of malaria in US Army Rangers returning from Afghanistan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10481157" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : How prevalent are Plasmodium ovale and P. malariae in East Asia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2151542" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Plasmodium ovale in Indonesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20380562" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Two nonrecombining sympatric forms of the human malaria parasite Plasmodium ovale occur globally.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34082791" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Global trend of Plasmodium malariae and Plasmodium ovale spp. malaria infections in the last two decades (2000-2020): a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17459775" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Plasmodium malariae and Plasmodium ovale--the "bashful" malaria parasites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29020345" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Plasmodium malariae in Israeli Travelers: A Nationwide Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14531987" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Late symptomatic Plasmodium malariae relapse in the territory of the former Yugoslavia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26720002" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Plasmodium malariae Infection Associated with a High Burden of Anemia: A Hospital-Based Surveillance Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15504824" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Chloroquine resistance in Plasmodium vivax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9230792" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2572903" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Plasmodium vivax resistance to chloroquine?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12875290" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17028048" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27107287" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Efficacy of Artesunate-mefloquine for Chloroquine-resistant Plasmodium vivax Malaria in Malaysia: An Open-label, Randomized, Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20152016" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Evaluation of chloroquine therapy for vivax and falciparum malaria in southern Sumatra, western Indonesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25213732" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25213732" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12114045" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Chloroquine-resistant Plasmodium malariae in south Sumatra, Indonesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24837880" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Detection of persistent Plasmodium spp. infections in Ugandan children after artemether-lumefantrine treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24837880" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Detection of persistent Plasmodium spp. infections in Ugandan children after artemether-lumefantrine treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23199488" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Plasmodium vivax: clinical spectrum, risk factors and pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22540175" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The anaemia of Plasmodium vivax malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25569250" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Parasite biomass-related inflammation, endothelial activation, microvascular dysfunction and disease severity in vivax malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25170106" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Severe malarial thrombocytopenia: a risk factor for mortality in Papua, Indonesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18148070" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Pathology of the ruptured spleen in acute vivax malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16501903" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Spontaneous splenic rupture, in tertian malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17437476" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Spontaneous splenic rupture due to Plasmodium vivax in a traveler: case report and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23721247" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Vivax malaria and bacteraemia: a prospective study in Kolkata, India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1681259" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Spontaneous splenic rupture due to Plasmodium ovale malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17446159" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : [Severe imported malaria: the experience of the Avicenna military hospital of Marrakech].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11548081" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Parasitic procrastination: late-presenting ovale malaria and schistosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7751755" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : [A case of Plasmodium ovale malaria with thrombocytopenia and an abnormality grade in FDP concentration despite the use of chloroquine as a malaria prophylaxis].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13850078" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Possible aetiological role of Plasmodium malariae in "nephrotic syndrome" in Nigerian children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7011214" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Immunological aspects of nephrotic syndrome in northern Nigeria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2217664" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Clinicopathological features of childhood nephrotic syndrome in northern Nigeria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9449730" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Plasmodium malariae infection in an asymptomatic 74-year-old Greek woman with splenomegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1454769" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : [Nephrotic syndrome caused by Plasmodium malariae infection. A case with favourable outcome].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17225845" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Childhood nephrotic syndrome: change in pattern and response to steroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17205283" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Malaria-induced renal damage: facts and myths.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18424865" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Acute renal failure in Plasmodium malariae infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14561793" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Delayed onset of malaria--implications for chemoprophylaxis in travelers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29228132" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Vivax Malaria Chemoprophylaxis: The Role of Atovaquone-Proguanil Compared to Other Options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24731298" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Geographical variation in Plasmodium vivax relapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25495607" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : The clinical and public health problem of relapse despite primaquine therapy: case review of repeated relapses of Plasmodium vivax acquired in Papua New Guinea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18403267" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Plasmodium vivax in India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23809889" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : The activation of vivax malaria hypnozoites by infectious diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30587297" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29771281" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : High Risk of Plasmodium vivax Malaria Following Splenectomy in Papua, Indonesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34042394" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Hidden Biomass of Intact Malaria Parasites in the Human Spleen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5131690" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Relapse activity in sporozoite-induced infections with a West African strain of Plasmodium ovale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5901625" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : A recently isolated West African strain of plasmodium ovale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14072436" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : A LONG-DELAYED PRIMARY ATTACK OF OVALE MALARIA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34216464" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Relapse of Plasmodium vivax and Plasmodium ovale Malaria With and Without Primaquine Treatment in a Nonendemic Area.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31066448" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Prospective Clinical and Molecular Evaluation of Potential Plasmodium ovale curtisi and wallikeri Relapses in a High-transmission Setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6228739" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Reduction of suppressor T lymphocytes in the tropical splenomegaly syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3227550" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Splenectomy in massive tropical splenomegaly: two-to six-year follow-up in 14 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12828005" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : [New concepts in hyperactive malarial splenomegaly].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Hyperreactive malarial splenomegaly: part I</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17906843" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : A case of hyper-reactive malarial splenomegaly. The role of rapid antigen-detecting and PCR-based tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2698886" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : A study on tropical splenomegaly syndrome and chloroquine prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7030559" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Tropical splenomegaly. Part 1: Tropical Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17516399" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Fever in returned travelers: results from the GeoSentinel Surveillance Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7717795" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Imported malaria. Clinical presentation and examination of symptomatic travelers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17538895" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33146932" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Rapid diagnostic tests for Plasmodium vivax malaria in endemic countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29554284" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : A Systematic Review: Performance of Rapid Diagnostic Tests for the Detection of Plasmodium knowlesi, Plasmodium malariae, and Plasmodium ovale Monoinfections in Human Blood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26376713" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Molecular malaria diagnostics: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15980019" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Anemia and thrombocytopenia in children with Plasmodium vivax malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16757648" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Diagnosis of mixed Plasmodium malariae and P. vivax infection in a development aid volunteer by examination of bone-marrow specimens by real-time PCR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19009202" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Chronic Plasmodium vivax infection in a patient with splenomegaly and severe thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19895296" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Invasion of erythroblasts by Pasmodium vivax: A new mechanism contributing to malarial anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Changes in bone marrow in malaria-a prospective study of 47 cases</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Changes in bone marrow in malaria-a prospective study of 47 cases</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Changes in bone marrow in malaria-a prospective study of 47 cases</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20937779" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : In vivo and in vitro efficacy of chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30033231" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24163021" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31584960" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17519416" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Treatment of malaria in the United States: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9333075" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Pyronaridine for treatment of Plasmodium ovale and Plasmodium malariae infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17212060" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Parasitological and clinical efficacy of standard treatment regimens against Plasmodium falciparum, P. vivax and P. malariae in Papua New Guinea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12407136" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Evidence for the efficacy of artesunate in asymptomatic Plasmodium malariae infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20409302" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22002979" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23044287" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Phenotypic and genotypic characterisation of drug-resistant Plasmodium vivax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28510573" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10817728" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Therapeutic responses to different antimalarial drugs in vivax malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20510281" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Artemisinin combination therapy for vivax malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17336652" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19064624" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : A trial of combination antimalarial therapies in children from Papua New Guinea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23926329" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : A randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine combined with primaquine for radical treatment of vivax malaria in Sumatera, Indonesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17366451" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27988484" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Fixed-Dose Artesunate-Amodiaquine Combination vs Chloroquine for Treatment of Uncomplicated Blood Stage P. vivax Infection in the Brazilian Amazon: An Open-Label Randomized, Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16575721" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Mefloquine is highly efficacious against chloroquine-resistant Plasmodium vivax malaria and Plasmodium falciparum malaria in Papua, Indonesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12384852" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Atovaquone/proguanil therapy for Plasmodium falciparum and Plasmodium vivax malaria in Indonesians who lack clinical immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22900786" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Primaquine radical cure of Plasmodium vivax: a critical review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24163057" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28749773" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Hemolytic Potential of Tafenoquine in Female Volunteers Heterozygous for Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency (G6PD Mahidol Variant) versus G6PD-Normal Volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30753364" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Clinical Spectrum of Primaquine-induced Hemolysis in Glucose-6-Phosphate Dehydrogenase Deficiency: A 9-Year Hospitalization-based Study From the Brazilian Amazon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30952158" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31327563" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32816320" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37748496" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28170391" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Haemolysis in G6PD Heterozygous Females Treated with Primaquine for Plasmodium vivax Malaria: A Nested Cohort in a Trial of Radical Curative Regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34871570" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with Plasmodium vivax malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34871570" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with Plasmodium vivax malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16968913" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31549159" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Hemolytic Dynamics of Weekly Primaquine Antirelapse Therapy Among Cambodians With Acute Plasmodium vivax Malaria With or Without Glucose-6-Phosphate Dehydrogenase Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37672548" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Weekly primaquine for radical cure of patients with Plasmodium vivax malaria and glucose-6-phosphate dehydrogenase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15494911" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Primaquine therapy for malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37748497" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30882150" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Efficacy of Primaquine in Preventing Short- and Long-Latency Plasmodium vivax Relapses in Nepal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35353962" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Higher-Dose Primaquine to Prevent Relapse of Plasmodium vivax Malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26416229" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : The challenges of introducing routine G6PD testing into radical cure: a workshop report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29552643" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Diagnostic performances of the fluorescent spot test for G6PD deficiency in newborns along the Thailand-Myanmar border: A cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23537118" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33306921" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Tafenoquine: a toxicity overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31366609" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : 8-Aminoquinoline Therapy for Latent Malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29590311" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Primaquine Pharmacokinetics in Lactating Women and Breastfed Infant Exposures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36906121" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Ultra-short course, high-dose primaquine to prevent Plasmodium vivax infection following uncomplicated pediatric malaria: A randomized, open-label, non-inferiority trial of early versus delayed treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12643993" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Can primaquine therapy for vivax malaria be improved?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21323159" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Directly observed therapy with primaquine to reduce the recurrence rate of plasmodium vivax infection along the Thai-Myanmar border.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28850568" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31274189" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31751320" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Guidance for Using Tafenoquine for Prevention and Antirelapse Therapy for Malaria - United States, 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24360369" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30650322" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30650326" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28893237" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Methods for the field evaluation of quantitative G6PD diagnostics: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37236221" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Tafenoquine co-administered with dihydroartemisinin-piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37236221" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Tafenoquine co-administered with dihydroartemisinin-piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31366382" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12377597" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : The assessment of antimalarial drug efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27016470" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Primaquine pharmacology in the context of CYP 2D6 pharmacogenomics: Current state of the art.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24088113" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27388693" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Prediction of CYP2D6 phenotype from genotype across world populations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30646129" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for Latent Plasmodium vivax Malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26888075" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25925423" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : The hyper-reactive malarial splenomegaly: a systematic review of the literature.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
